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ABSTRACT
Neurotrophic factors play essential role in the development and functioning of the ner-
vous system and other organs. Glial cell line-Derived Neurotrophic Factor (GDNF) 
family ligands (GFLs) are of particular interest because they promote the survival of 
dopaminergic neurons in vitro, in Parkinson’s disease animal models and in patients. 
GDNF is also a potent survival factor for the central motoneurons and thus is considered 
as a potential lead for the treatment of amyotrophic lateral sclerosis. The survival pro-
moting receptor complex for GFLs consists of a ligand-speci? c co-receptor, GFR? and a 
signal transducing module, receptor tyrosine kinase RET. At least GDNF and persephin, 
a GFL, have established functions outside central nervous system. GDNF is crucial for 
enteric nervous system and kidney development as well as for spermatogenesis. Perse-
phin controls calcitonin secretion.
Communication between cells often occurs in the extracellular matrix (ECM), a 
meshwork, which is secreted and deposited by the cells and is mainly composed of ? bril-
lar proteins and polymerized sugars. We evaluated the relationship between GFLs and 
extracellular matrix components and demonstrated that three GFLs - GDNF, neurturin 
and artemin bind heparan sulfates with nanomolar af? nities. The fourth member of the 
family - persephin binds these polysaccharides thousand times less tightly.  GDNF, neur-
turin and artemin also bind with high af? nity to heparan sulfate proteoglycan (HSPG) 
isolated from the nervous system, syndecan-3. 
GDNF signals through HSPGs, evoking Src family kinase activation. This signaling 
induces cell spreading, hippocampal neurite outgrowth in vitro and cellular migration. 
Speci? cally, GDNF signaling through syndecan-3 is important for embryonic cortical 
neuron migration. Syndecan-3-de? cient mice, similarly to mice lacking GDNF, have 
less GABAergic neurons in their cortex, as compared to the wild-type mice. This fact 
provides indirect evidence that GDNF interaction with syndecan-3 is important for corti-
cal brain development. Noteworthy, in non-neuronal tissues GFLs may signal via other 
syndecans. 
We also present the structural model for a GDNF co-receptor, GFR?1. The X-ray 
structure of the GFR?1 domain 3 was solved with 1.8 Å resolution, revealing a new pro-
tein fold. Later we also solved the structure of the truncated GFR?1 in the complex with 
GDNF and this model was con? rmed by site-directed mutagenesis. 
In summary, our work contributed to the structural characterization of GFR?-based 
receptor complex and revealed a new receptor for GDNF, neurturin and artemin – the 
HSPG syndecan-3. This information is critically important for the development of 
GFR?/RET agonists for the treatment of neurodegenerative diseases.

11. LITERATURE REVIEW
1.1. Growth factors and neurotrophic 
factors
In October 1986, the Italian developmental 
biologist Rita Levi-Montalcini and the 
American biochemist Stanley Cohen were 
awarded the Nobel Prize in Physiology 
or Medicine for “their discovery of 
growth factors: nerve growth factor 
(NGF) and epidermal growth factor 
(EGF), respectively”. The discovery of 
NGF was made while working in Viktor 
Hamburger’s laboratory in the USA. First, 
Levi-Montalcini demonstrated that when 
tumors from mice were transplanted to 
chick embryos they promoted a potent 
growth of chick embryo nervous system, 
speci? cally of the sensory and sympathetic 
nerves. When Stanley Cohen joined 
the laboratory they showed that snake 
venom promoted growth of the neurites 
in chicken sympathetic ganglia explants 
even more potently than tumor extracts. 
NGF from snake venom was puri? ed and 
characterized. It was also the major nerve 
growth-promoting factor in tumor extracts 
(Cohen and Levi-Montalcini, 1956). 
Later, Cohen observed an unexpected 
acceleration of development when he 
injected salivary gland extract to newborn 
mice - it stimulated the proliferation 
of epithelial cells in skin and cornea. 
Cohen termed this substance epidermal 
growth factor (The Nobel Assembly at the 
Karolinska Institute, Press release, 1986).
NGF was the ? rst of many growth-
regulating signal substances to be 
discovered and characterized. These 
substances are collectively known as 
growth factors (GFs): “any of various 
chemicals, particularly polypeptides, that 
have variety of roles in the stimulation of 
new cell growth and cell maintenance” 
(Oxford Dictionary of Science, Oxford 
University Press, 2003). 
Ironically, the ? rst growth factor NGF 
does not fall precisely into this de? nition. 
NGF promotes axonal outgrowth but 
generally not a cell proliferation (with 
the exception of certain neuroblasts and 
lymphocytes). Accounting for this, it may 
be more appropriate to use the following 
definition of the growth factor: Small 
secreted protein that promotes cell growth, 
propagation, differentiation, survival, 
migration and process formation in the 
cells expressing cognate receptors for a 
given GF.
Growth factors are synthesized ? rst 
as precursors, followed by maturation 
through proteolytic removal of the “Pro” 
region (Fig. 1A). Proteolytic cleavage 
occurs either in the Golgi or in the 
extracellular space by the extracellular 
matrix proenzyme convertases (e.g. 
metalloproteases) or plasmin upon release 
of the GF (Chang and Werb, 2001). The 
biologically active form of most GFs is a 
homodimer, which is formed immediately 
after synthesis in the endoplasmic 
reticulum. GFs exert their biological 
effects often through receptor tyrosine or 
serine-threonine kinases, the large single-
pass transmembrane proteins. Receptor 
kinases are often activated by dimerization 
induced by GF binding to their 
extracellular domains. Upon dimerization 
of the receptor, transphosphorylation of 
certain amino acid residues in the catalytic 
intracellular domain (ICD) of the receptor 
takes place. This leads to the recruitment 
of a number of adaptor proteins or 
enzymes that assist activation of the 
signaling cascades, leading to a variety of 
biological effects.
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Fig. 1. Structures of GDNF family ligands and neurotrophins. A. Gross structure of GDNF and 
NGF pre-pro polypeptides. B. Representation of X-ray structures of GDNF, ARTN, NGF and 
BDNF/NT3 (Eigenbrot and Gerber, 1997; Wang et al., 2006; McDonald et al., 1991; Robinson et 
al., 1995) and homology models of NRTN, and PSPN. Homology models were generated using 
I-TASSER server (Zhang, 2008)  and visualized with PyMol (DeLano Scienti? c).
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3The ? rst isolated GF is also the very 
? rst neurotrophic factor (NF). NGF was 
initially demonstrated to promote neurite 
outgrowth of sensory and sympathetic 
neurons (Levi-Montalcini and Cohen, 
1956). Later, NGF was also demonstrated 
to promote survival of these neurons 
(Levi-Montalcini and Booker, 1960; 
Levi-Montalcini and Angeletti, 1963).
Therefore, NGF is the prototype protein 
for the family of neurotrophins. Strictly 
speaking NFs are growth factors that 
support the survival of neurons by 
activating speci? c cell-surface receptors. 
However, many other GFs that were 
traditionally thought to have functions 
elsewhere in the organism were shown 
to have a survival promoting effect on a 
number of neuronal populations (Barde, 
1989; Digicaylioglu and Lipton, 2001; 
Jin et al., 2005; Mendez et al., 2005). 
The opposite is true as well. Outside the 
nervous system, NFs stimulate processes 
generally attributed to other GFs (Meng 
et al., 2000; Vega et al., 2003). This 
observation highlights the remarkable 
similarity in the signaling of the receptor 
kinases in different tissues and raises 
the question about the specificity of 
their downstream signaling, induced by 
different GFs.
Current classification defines four 
major families of NFs: neurotrophins, 
neurokines, GDNF family ligands and 
CDNF/MANF neurotrophic factors 
(Lindholm et al., 2007). 
NGF is a founding member of the 
neurotrophin family of proteins. They 
play many roles in the development of 
the organism as well as in the adulthood. 
Brain-Derived Neurotrophic Factor 
(BDNF), Neurotrophin-3 (NT3) and 
Neurotrophin-4 (NT4) are the other 
members of this family. The most profound 
function of these factors is to keep neurons 
alive. The importance of the neurotrophins 
for the organism becomes obvious when 
analyzing respective knockout mice. 
NGF-de? cient mice, for example, have a 
massive loss (95%) of superior cervical 
ganglion (SCG) sympathetic neurons 
(Crowley et al., 1994). Mice lacking 
bdnf gene suffer from a 80% loss of 
sensory neurons in vestibular ganglion 
(Ernfors et al., 1994). Survival promoting 
effects of neurotrophins are mediated by 
receptor tyrosine kinases (RTK) named 
tropomyosin-related kinase (Trk). NGF 
preferentially activates TrkA receptor, 
BDNF and NT4 share TrkB receptor, 
whereas NT3 activates TrkC. 
The study of the neurotrophins led 
to the concept aiming to explain the 
regulatory mechanisms that control the 
neuronal number by the functionality 
of their connections. The concept is 
known as the “target field hypothesis” 
(Korsching, 1993; Lewin and Barde, 
1996) and is based on the fact that early 
in the development peripheral nervous 
systems (PNS) neurons are overproduced. 
Roughly half of the neurons, those that 
fail to establish functional connection with 
the target tissue (for example to innervate 
the muscle), will die via apoptosis. The 
selection of the neurons occurs on the 
basis of accessibility of the trophic factors, 
which are produced at the limited amounts 
by the target tissue. Only those neurons 
that establish functional connections 
with the target tissue receive enough 
trophic support to survive. Importantly, 
this concept underlines the neurotrophic 
factor-regulated mechanism ensuring 
apoptotic elimination of the neurons that 
fail in communication. The ? ndings that 
NF overexpression in muscles leads to 
increased innervation of neuromuscular 
junction (Keller-Peck et al., 2001; Nguyen 
et al., 1998) and that NF-de? ciency results 
Literature Review
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in decreased innervation and number of 
neurons (Huang and Reichardt, 2003) 
advocate for the target ? eld hypothesis. 
However, in the central nervous system 
(CNS) this concept is not yet well 
established (Kramer et al., 2007).
In the CNS, neurotrophins act as 
neuromodulators for synaptic transmission 
and plasticity. Upon activity-regulated 
release of neurotrophins into the synaptic 
cleft they in turn induce immediate changes 
in synaptic ef? cacy and morphology. This 
leads to long-term functional and structural 
modi? cations of the synapses (reviewed 
by Poo, 2001; Arancio and Chao, 2007). 
Therefore, neurotrophins were considered 
for the treatment of CNS disorders. 
NGF and BDNF are trophic factors for 
cholinergic neurons, the primary neuronal 
population in the brain that degenerates in 
Alzheimer’s disease (AD). 
For example, BDNF was tested 
in Parkinson’s disease (PD), AD and 
amyotrophic lateral sclerosis (ALS). NGF-
blocking antibodies are in clinical trial 
against chronic pain (Dray, 2008). Another 
clinical trial, which took advantage of 
NGF-overexpressing cells transplantation, 
demonstrated the bene? t for the patients 
suffering from AD (Tuszynski et al., 
2005).
N e u r o t r o p h i n s  ( a n d  p r o -
neurotrophins) also bind low affinity 
neurotrophin  receptor p75, a non-tyrosine 
kinase receptor of the tumor necrosis factor 
receptor superfamily (TNFR-SF). p75 
interacts with neurotrophins either directly 
or modulates the af? nity and speci? city of 
the Trk receptors for neurotrophins (Huang 
and Reichardt, 2003). The data on the role 
of p75 is to some extent controversial not 
the least because p75 can be in? uenced by 
co-receptors NgR/Lingo1 (Mi et al., 2004; 
Vilar et al., 2009) and sortilin (Nykjaer et 
al., 2004). ProNGF triggers cell death via 
p75/sortilin and mediates axonal growth 
inhibition via NgR/Lingo1. In the absence 
of Trk, p75 activation leads to apoptosis 
of certain neurons, however, in other 
neuronal populations solely expressing 
p75 activation leads to survival (Dechant 
and Barde, 2002; Rabizadeh and Bredesen, 
2003).
Neurotrophins have several functions 
outside the nervous system. For example, 
NGF is known to regulate the function of 
the immune system (Vega et al., 2003). 
BDNF has a function in vascular system 
(Donovan et al., 2000) and hair follicle 
development (Botchkarev et al., 2004).
Another group of neurotrophic 
factors – the neurokines, consist of ciliary 
neurotrophic factor (CNTF), interleukin-6 
and -11 (IL-6 & IL-11), leukemia 
inhibitory factor (LIF, CDL), oncostatin M, 
cardiotrophin-1 (CT-1), CT-like cytokine 
and neuropoietin (Halvorsen and Kaur, 
2006) These NFs are cytokines, which 
are produced by immune cells, Schwann 
cells, fibroblasts and sensory neurons. 
Similarly to neurotrophins, neurokines 
act as mediators between nervous system 
and immune system by inducing response 
to injury and stress. Several neurokines 
like CNTF, IL-6 and CT-1 have profound 
effects on motoneurons, supporting 
their survival (Oppenheim, 1996). All 
neurokines exert their action via a 2- or 
3-component receptor system. They all 
share non-tyrosine kinase receptor gp130 
(Taga and Kishimoto, 1997). However, 
CNTF binding to gp130 requires a cell 
surface glycosyl-phosphatidylinositol 
(GPI)-anchored co-receptor CNTFR?
(Davis et al., 1991) and LIFR??(Halvorsen
and Kaur, 2006). Likewise, binding of IL-6 
to gp130 is mediated by a transmembrane 
co-receptor IL-6R? (Taga et al., 1989).
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1.2. GDNF family ligands
GFLs structure and receptor complexes
The third group of neurotrophic factors 
is GDNF family ligands (GFLs), which 
consist of GDNF and the homologous 
neurotrophic factors neurturin (NRTN), 
artemin (ARTN) and persephin (PSPN). 
GFLs are structurally and evolutionary 
different from other NFs (Fig. 1). They are 
distant relatives of the TGF-? superfamily. 
They contain seven cysteine residues with 
the similar relative spacing characteristic 
for TGF-?. Six cysteines form three 
intermolecular disulphide bonds (cystines) 
and the seventh cysteine is involved in the 
homodimer formation.  GFLs and TGF-?s
(and neurotrophins) share the structural 
motif known as cystine-knot (Eigenbrot 
and Gerber, 1997), in which a covalent 
ring formed by two cystines and a third 
cystine passing through it (McDonald 
et al., 1991). The cystine knot forms 
intracellularly and prevents the formation 
of a globular structure commonly found 
in other extracellular polypeptides (Vitt 
et al., 2001). All known structures for 
TGF-? superfamily members share 
the following structural features: The 
?-sheets comprising two “fingers” and 
the ?-helix connected to cysteine knot via 
flexible loops. GDNF poses the unique 
38 amino-acids-long protrusion, which 
is not visible in the crystal structure 
due to high flexibility or disordered 
structure (Eigenbrot and Gerber, 1997). 
The 92RRLTSDK sequence in the loop 
connecting C–terminus of the ?-helix with 
a cystine knot is also missing from their 
X-ray structure.
The resolved and modeled structures 
of other GFLs resemble the structure of 
GDNF (Fig.1B). ARTN has a different 
angle between ?-helix and ? ngers (Wang 
et al., 2006). The amino acid determinants 
of the GFLs interaction with their receptors 
are on the GFLs ? ngers (Eketjäll et al., 
1999). These amino acids contribute to 
electrostatic and hydrophobic components 
of the free energy of the interaction. 
According to the presented models of 
the GFLs, the tertiary structure of this 
region does not vary signi? cantly among 
GLFs and several amino acids important 
for the interaction are either identical or 
complementary. 
Most TGF-?’s use transmembrane 
receptor serine-threonine kinases to 
transduce their signal. GFLs use different 
receptors for signal transduction. Their 
receptor complex consists of the signaling 
component RET, a receptor tyrosine kinase 
that is commonly shared by the four GFLs. 
However, GFLs do not bind directly to 
RET. To present the corresponding GFL 
to RET, the ligand-speci? c surface-bound 
GDNF family co-receptor alpha (GFR?)
is required. GFR?s are GPI-anchored 
proteins as the co-receptor (CNTFR?) in 
CNTF receptor system (Davis et al., 1991; 
Jing et al., 1996).
 GDNF preferentially binds to 
GFR?1, NRTN to GFR?2, ARTN to 
GFR?3 and PSPN to GFR?4 (Fig. 2), 
followed by GFR?/RET receptor complex 
oligomerization (or complex stabilization) 
and transphosphorylation (Airaksinen and 
Saarma, 2002; Sariola and Saarma, 2003).
Paratcha et al. (2003) found that the 
neural cell adhesion molecule (NCAM) 
in the complex with GFR? functions 
as an alternative signaling receptor for 
GFLs. NCAM-mediated GDNF signaling 
leads to activation of cytoplasmic Src-
family kinases (SFK) and subsequently to 
enhanced neuronal migration and neurite 
outgrowth. Although the vast majority 
of GFL signaling utilizes GFR?/RET or 
GFR?/NCAM receptor systems, the data 
indicated that additional, still unidenti? ed 
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GFL signaling pathways may exist. In that 
study, GDNF promoted differentiation 
and tangential migration of cortical 
GABAergic neurons in RET- and NCAM-
independent manner (Canty et al., 2009; 
Pozas and Ibáñez, 2005).
Fig. 2. GDNF family ligands (GFLs) and their receptors. GFLs cannot bind the signal-transducing 
receptor RET directly but require glycosylphosphatidylinositol (GPI)-anchored co-receptor 
GFR?. GDNF preferentially binds to GFR?1, neurturin (NRTN) to GFR?2, artemin (ARTN) to 
GFR?3 and persephin (PSPN) to GFR?1. They all rely on a common receptor tyrosine kinase 
RET to transduce their signal. RET consists of four cadherin-like domains (CLDs), the cysteine-
rich domain (CRD), the transmembrane domain (TM) and an intracellular part with the tyrosine 
kinase domain. RET CDLs and CRD were modeled using EC-cadherin as a template and laminin 
gamma 1 chain, respectively, by HHpred program (Söding et al., 2005). GFR?2 and GFR?4
homology models were generated by I-TASSER server. Calcium (yellow circle) is bound between 
CLD2 and CLD3 of RET (Anders, 2001). All proteins were visualized by ViewerLite (Accelrys) 
program and are represented as solid ribbons.
TM
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GFR 1 GFR GFR GFR
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Biological effects and therapeutic 
potential of GFLs
GFLs have all been shown to act as potent 
neuronal survival factors, but at least 
GDNF and PSPN have several functions 
outside the nervous system. Gene ablation 
shows that GDNF is crucially important 
for the development of the enteric nervous 
system (ENS)  (Moore et al., 1996; Pichel 
et al., 1996; Sánchez et al., 1996) and for 
sensory neurons (Erickson et al., 2001). 
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et al., 1996). Unlike GDNF, NRTN fails 
to induce neurite sprouting in vivo or 
the neuronal hypertrophy (Åkerud et 
al., 1999). Nevertheless, NRTN holds a 
promise for Parkinson’s disease therapy 
(Marks et al., 2008; Ceregene Inc., 
Press release, 2009) and for epilepsy 
(Nanobashvili et al., 2000). In addition, 
NRTN promotes the survival of basal 
forebrain cholinergic neurons (Golden 
et al., 2003) and spinal motor neurons 
(Garces et al., 2000). Thus, NRTN has 
potential in treatment of Alzheimer’s 
disease and ALS. NRTN is important for 
the development and maintenance of the 
parasympathetic neurons (Rossi et al., 
1999). In addition, similarly to GDNF, 
NRTN and GFR?2 mediate innervation of 
the gut by enteric neurons as demonstrated 
by gene ablation (Heuckeroth et al., 1999; 
Rossi et al., 1999).
ARTN acts as a chemoattractant 
for sympathetic neurons and gut 
haematopoietic cells (Veiga-Fernandes 
et al., 2007). In the absence of ATRN 
signaling SCG neurons are misguided 
because they lack guidance clues to 
reach their target. ARTN also supports 
the survival of sensory neurons and has 
a therapeutic potential for treatment of 
neuropathy (Gardell et al., 2003; Wang et 
al., 2008). ARTN is currently in Phase I 
clinical trial by Biogen Idec/NsGene for 
chronic pain (NsGene’s Press release, 
2009)
PSPN promotes the survival of mouse 
embryonic basal forebrain cholinergic 
neurons in vitro (Golden et al., 2003). 
Hence, PSPN may be useful for the 
treatment of Alzheimer’s disease. In vivo,
PSPN regulates calcitonin production by 
thyroid C-cells (Lindfors et al., 2006). 
PSPN can promote the survival of 
dopaminergic neurons (Milbrandt et al., 
1998; Åkerud et al., 2002; Zihlmann et 
Mice lacking GDNF or its receptors have a 
loss of motor neurons (Garces et al., 2000; 
Oppenheim et al., 2000) and defects of 
parasympathetic nervous system (Enomoto 
et al., 2000). GDNF is absolutely required 
for kidney formation (Moore et al., 1996; 
Pichel et al., 1996; Sánchez et al., 1996) 
and play a pivotal role in the regulation of 
spermatogenesis (Meng et al., 2000).
GDNF was initially puri? ed from glial 
cell line supernatant and shown to support 
the survival of the midbrain dopaminergic 
neurons in vitro (Lin et al., 1993). In 
animal models of Parkinson’s disease 
GDNF efficiently rescues dopamine 
neurons and it has shown promising 
results in two clinical trials (Gill et al., 
2003; Patel et al., 2005; Slevin et al., 
2005). Another study failed to demonstrate 
a clear clinical bene? t of GDNF (Lang et 
al., 2006), which may be explained by the 
con? guration of the catheter used to infuse 
GDNF (Salvatore et al., 2006). GDNF is 
also a potent survival factor for central 
motoneurons and, therefore, it may have 
clinical ef? cacy in the treatment of ALS 
(Henderson et al., 1994; Oppenheim et al., 
1995). Current treatment of these diseases 
is symptomatic. Hence, GFLs represent 
a novel possibility for the treatment of 
Parkinson’s and ALS patients, as they are 
the most ef? cient molecules available that, 
in animal models, prevent death and repair 
neuronal populations affected in these 
diseases. Additional results highlight the 
importance of GDNF as a new target for 
the treatment of drug addiction (Airavaara 
et al., 2004; Messer et al., 2000) and 
alcoholism treatment (Carnicella et al., 
2009; He et al., 2005). Although the 
original paper by Messer and co-workers is 
considered controversial, the phenomenon 
deserves further investigation.
NRTN also supports the survival of 
the dopaminergic neurons (Kotzbauer 
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al., 2005). In addition, PSPN may have 
clinical applications in the treatment of 
stroke (Tomac et al., 2002).
1.3. GFLs receptors: GFR?/RET 
receptor complex
The RET oncogene was originally cloned 
by Masahide Takahashi and coworkers 
(1985) as a novel gene with transforming 
activity. The oncogenic activity appeared as 
the result of RET-encoded tyrosine kinase 
domain recombination with N-terminal 
domain bearing the dimerization motif of 
another gene. 
RET proto-oncogene encodes for 
the type I transmembrane RTK, which 
consist of four cadherin-like domains, 
membrane-proximal cysteine-rich domain 
and intracellular tyrosine kinase domain 
(Anders et al., 2001) (Fig. 2). 
Mechanism of RET activation
The classic hypothesis implies RTK 
activation occurs when a dimeric ligand 
binds simultaneously to two receptor 
molecules, inducing their dimerization. 
Receptor dimerization is further stabilized 
by additional receptor-receptor interactions 
(Schlessinger, 2000). Dimerization of 
the receptors leads to the association of 
tyrosine kinase domains and subsequent 
transphosphorylation of the activating 
loops of the kinases. This in turn renders 
a conformational change in the kinase 
domain structure unleashing the full kinase 
activity of the enzyme (Hubbard, 2004). 
However, there are several exceptions 
from this concept. Insulin receptor family 
are covalently-linked heterotetramers (Van 
Obberghen, 1994). They are activated by 
conformational change induced by the 
ligand (Hubbard, 2004). Another exception 
is EGF receptor (EGFR). Its extracellular 
domain (ECD) assumes a folded 
configuration in the absence of ligand, 
which efficiently prevents spontaneous 
dimerization and activation of the receptor 
(Ferguson et al., 2003). Upon ligand 
binding a conformational change occurs 
that is likely to involve rotation of the 
transmembrane ?-helices and concomitant 
realignment of the cytoplasmic domains. 
Realigned kinase domains of the EGFR 
are more likely to transphosphorylate each 
other (Moriki et al., 2001).
Erythropoietin (Epo) is a cytokine, 
which has neurotrophic factors activities 
(Digicaylioglu and Lipton, 2001). Epo 
receptor (EpoR) is a non-tyrosine kinase 
receptor associated constitutively with 
the tyrosine kinase JAK2. Unliganded 
ECD of the EpoR exists as a non-covalent 
dimer in a X-shaped conformation with 
wide gap between the membrane proximal 
domains, which are oriented at an angle 
of 135° and transmembrane domains are 
separated by 73Å (Livnah et al., 1999). 
This separates JAK2 kinases making the 
transphosphorylation unlikely. When the 
ligand binds to the receptor, the X-shaped 
conformation of the ECD changes to the 
Y-shape and the gap closes (30Å). Thus, 
JAK2 kinases are placed in proximity of 
each other and become fully active (Remy 
et al., 1999). Hence, while dimerization 
is required, it is not always suf? cient for 
receptor activation. 
Unliganded RTKs always have a basic 
level of activity, as auto-phosphorylation 
of RTK can be enhanced by tyrosine 
phosphatase inhibitors or by receptor 
overexpression even in the absence of 
ligand binding (Runeberg-Roos et al., 
2007; Schlessinger, 2000). It is logical to 
assume that the receptor monomers are in 
the equilibrium with the receptor dimers 
(inactive dimer). Inactive dimers are in 
turn in the equilibrium with a population 
of the receptor dimers existing in a 
con? guration of their ECD and TK that 
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are compatible with transphosphorylation 
(active dimer) (Fig. 3). Hence, unlike the 
wide-spread “all-or-nothing” mechanism, 
the activation of the RTK by the ligand is 
“all-or-something”.
The extracellular domain of RET 
is very different from other RTKs. It 
lacks leucine zipper, immunoglobulin or 
fibronectin-like domains, which are the 
characteristics of most RTK’s ECD. RET 
ECD harbors four cadherin-like domains 
and is similar to the cadherin family of cell 
adhesion molecules, sharing up to 40% of 
homology (Anders et al., 2001). Cadherin’s 
functioning depends on calcium. Ca2+ 
binds in the cleft between domains thus 
rigidifying and linearizing the molecule. 
According to the RET model by Anders 
and colleagues (2001), Ca2+ binds in-
between cadherin-like domain two and 
three and is required for GDNF-induced 
RET activation. Ca2+ binding to this 
position would make connection between 
second and third domains rather rigid but 
Fig. 3. Activation modes of RTKs. Free receptor monomers are in a dynamic equilibrium with 
the dimerized receptors. Some of the dimers are active while the others are inactive. In the 
presence of the speci? c ligand the balance shifts towards active dimers and results in biologically 
signi? cant signaling (after Schlessinger, 2000).
??
? ?
?????????
????????
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would permit other domains flexibility. 
Another study suggests that Ca2+ binding 
to cadherins promotes dimerization of 
cadherin domains (Nagar et al., 1996) and 
may be important for the stabilization of 
RET dimerization upon ligand binding. 
Activation of RET, similarly to 
the activation of other RTKs, requires 
dimerization. Evidence that dimerization 
alone is sufficient for activation comes 
from the oncogenic form of RET. Germline 
missense mutations in the RET gene cause 
multiple endocrine neoplasia type 2A 
(MEN2A) by producing constitutively 
active disul? de-bonded dimer (Mulligan 
et al., 1994). All mutations known to cause 
MEN2A are in the extracellular cysteine-
rich domain of RET. MEN2A mutations 
involve cysteine substitutions in positions 
609, 611, 618, 620, 630 and the most 
common mutation for MEN2A - cysteine 
634 substitution by arginine (Marx, 
2005). This mutation eliminates one of 
the cysteines, which normally makes 
intramolecular disul? de bond with another 
cysteine. This allows the unpaired cysteine 
to participate in the intermolecular reaction 
to generate an active oncogenic dimer. RET 
overexpression also leads to its activation 
in the absence of ligand apparently due 
to spontaneous dimerization (Liu et al., 
1996; Trupp et al., 1998; Runeberg-Roos 
et al., 2007).
 One of the plausible mechanisms that 
cells utilize to diminish possible adverse 
effects of the spontaneous unliganded 
RET activation may be its localization in 
the microenvironment incompetent for 
signaling. In the absence of the ligand, 
RET is located outside lipid rafts, which 
are small dynamic plasma membrane-
located “signalosomes”. Upon ligand 
binding RET is recruited to lipid rafts 
where it interacts with a variety of 
signaling molecules (Tansey et al., 2000).
The MEN2A form of RET is further 
activated by the administration of the 
ligand (Mograbi et al., 2001). This suggests 
that covalently-linked dimer exists with 
a suboptimal quaternary structure and 
that the ligand triggers a conformational 
change, realigning kinase domains for 
optimal transactivation. 
The most membrane-distant RET 
domain (? rst cadherin like domain; CLD1), 
is crucial for GDNF-induced activation 
(Kjær and Ibáñez, 2003). GDNF binds 
GFR?1 close to the membrane, whereas 
CLD1 domain of RET is perceived to be 
distant from the membrane. Therefore, this 
result suggests that RET bending towards 
plasma membrane is necessary for RET 
activation by the ligand. However, the 
study that used chemical cross-linking 
of purified receptor-ligand complexes 
followed by mass spectrometry finger-
printing revealed that the third cadherin-
like and cysteine-rich domains of RET are 
in direct contact with GFR?1 (Amoresano 
et al., 2005). The first cadherin-like 
domain of RET is separated from the 
second one by 10 amino acids and has 
profound solvent accessible surfaces with 
negative and positive charges (Anders et 
al, 2001). This fact hints that CLD1 may 
interact intramolecularly with CLD2 or 
CLD3 (and possibly have autoinhibitory 
function for unliganded RET as domain 
1 of FGFR). Alternatively, CLD1 may 
interact with another RET protomer (Fig. 
10) or with other molecules like heparin. 
Alternatively, the ? rst three cadherin-like 
domains may have stabilization function 
for the ligand-receptor complex or  create 
a tertiary structure permissive for ligand-
induced dimerization and activation. 
A question remains whether RET 
dimerization is sufficient for its full 
activation. This information is crucial for 
the design of RET agonists for clinical 
Literature Review
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applications. Therefore, structural 
information on the RET in complex with 
GFR?/GFL would be important to obtain.
Similarly to muscle-specific-kinase 
(MuSK) and unlike other RTKs, RET 
forms a multi-component signaling 
complex (Hubbard and Miller, 2007). The 
stoichiometry of the signaling complex 
is not known, but based on the fact that 
GFLs are covalently-linked dimers it 
was proposed by Jing et al. (1996) to be 
(GFL)2:(GFR?)2:(RET)2. Currently, there 
is no agreement whether the true ligand 
for RET is the GFR?/GFL complex or 
whether GFL is a ligand for the preformed 
GFR?/RET receptor complex (Schlee 
et al., 2006). This question is essential 
when considering the GFLs mimetics for 
the treatment of the neurodegenerative 
diseases. If the preformed GFR?/RET 
complex exists in biologically signi? cant 
concentration, the possible repertoire 
of targets for GFL-based drug design 
broadens. Bivalent molecules binding two 
monomeric GFR?s or small molecules that 
allosterically alter GFR?/RET structure 
inducing transphosphorylation may be 
clinically useful.
Supportive of the pre-formed complex 
hypothesis are the facts that GFR?1/RET 
–complex provides additional binding 
sites for GDNF compared to GFR?1 alone 
(Eketjäll et al., 1999). In the presence of 
RET GDNF binds to GFR?1 10 times more 
tightly (Cik et al., 2000). An alternative 
explanation of these facts is that GFR?1
in complex with RET might undergo a 
conformational change becoming more 
af? ne to GDNF.
Another evidence of this hypothesis 
was a ? nding that small molecules selected 
by competition with GDNF for GFR?1
binding site can act as RET agonists 
(Tokugawa et al., 2003). 
RET kinase domain
RET tyrosine kinase domain shares up to 
55% homology with other kinases and the 
crystal structure of inactive RET kinase 
domain represents a typical kinase fold 
(Knowles et al., 2006) (Fig. 4A, 4B). The 
structure also revealed an activation loop, 
which is a key structural element in the 
regulation of catalytic activity in many 
kinases. When unphosphorylated, the 
activation loop is usually not positioned 
optimally for phosphoryl transfer 
(reviewed by Hubbard and Till, 2000). 
The basal activity of the unphosphorylated 
kinase domain is low, but it is suf? cient for 
transphosphorylation to occur within the 
ligand-stabilized dimer (Hubbard, 2004). 
Transphosphorylation of the activation 
loop is accompanied by a conformational 
change that secures the domain in 
catalytically competent configuration 
(Johnson et al., 1996).  This happens in 
most kinases but not in RET.
The activation loop of RET contains 
two tyrosine residues at positions 900 and 
905 (Knowles et al., 2006). Both tyrosines 
were found to be phosphorylated in vitro
and Tyr-905 was proposed to stabilize the 
active conformation of the kinase (Iwashita 
et al., 1996; Pandey et al., 1995). However, 
the more recent biochemical data revealed 
only a moderate increase (3-4 times) of the 
kinase activity after phosphorylation of 
tyrosines in the activation loop (Knowles 
et al., 2006). It is, however, possible that 
tyrosine residues, which are used by 
downstream adaptors to relay the signal, 
are only effectively phosphorylated in 
trans. Thus, moderate increase in the 
activity of phospho-Tyr-905-RET may 
not fully re? ect the consequences for the 
downstream signaling. Another important 
feature of RET revealed by the crystal 
structure of its kinase domain posing RET 
in unique position was that no signi? cant 
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Fig. 4. RET kinase domain structure. 
A. Unphosphorylated “inactive” RET kinase. 
B. Phosphorylated “active” RET kinase domain.  Adenosine monophosphate (AMP) is shown 
in the binding pocket. Phosphotyrosine 905 in RET “activation loop” and methionine-918 are 
shown as sticks. 
C. Substrate binding pocket and catalytic center of the active RET-MEN2B kinase. Threonine in 
position 918 (instead of wild-type methionine, M918T) may stabilize bound substrate (orange 
ribbon with amino acids represented as sticks).
Inactive RET kinase Active RET kinase
A B
?
RET-MEN2B with substrate
Tyr-905
Met-918
AMP
M918T
Tyr-905
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difference between phosphorylated 
(active) and unphosphorylated forms was 
observed. These observations leave a 
question on the molecular mechanisms of 
RET kinase activation open.
Downstream signaling
GDNF binding to GFR?1/RET activates 
several pathways typical for RTK 
signaling. The cytoplasmic domain of 
the long isoform of RET contains 18 
tyrosine residues, twelve of which are 
phosphorylated upon receptor activation 
(Kawamoto et al., 2004; Liu et al., 1996). 
Phosphorylated residues Tyr905, 
Tyr981, Tyr1015, and Tyr1096 are the 
docking sites for Grb7/Grb10, Src, 
phospholipase C-? (PLC- ?), and Grb2, 
respectively (Alberti et al., 1998; Borrello 
et al., 1996; Encinas et al., 2004; Pandey 
et al., 1995; Pandey et al., 1996). Tyr1062 
has a broad spectrum of engaged effector 
proteins: IRS1/2, Dok1, Dok4/5, Dok6, 
Enigma, FRS2, and PKC-?, Shc and ShcC 
(reviewed by Santoro, 2004). There is 
evidence that also Tyr752 and 928 can be 
phosphorylated and may activate STAT3 
(Schuringa et al., 2001). The role of 
phosphorylation of Tyr806, 809, 826, 900, 
1029 and 1090 remains to be shown. 
The recruitment of these adaptor 
proteins activates a number of signaling 
pathways. For example this triggers 
Ras/RAF pathway, which leads to the 
activation of the mitogen-activated 
protein kinases ERK1 and ERK2, ERK5, 
p38MAPK, phosphatidylinositol 3-kinase 
(PI3K) and subsequent activation of the 
Akt-kinase, Jun NH2-terminal protein 
kinase (JNK) and PLC-?. These pathways 
lead to profound biological effects: cell 
survival, differentiation, growth and 
migration, among others.
Tyr1062 appears to be the most 
important  docking si te  for  RET 
functioning. Knock-in mice with 
Tyr1062Phe substitution revealed the 
phenotype similar to full RET knockout 
(Jijiwa et al., 2004; Wong et al., 2005). 
Tyr1015 also appears to be crucial as 
mice with Tyr1015Phe substitution have 
severe kidney defects (Jain et al., 2006) 
providing insights into the pathogenesis of 
congenital anomalies of kidneys and the 
lower urinary tract (CAKUT).
In response to an elevated level of 
cyclic AMP (cAMP) the receptor tyrosine 
kinase RET can be phosphorylated on 
serine 697 (or 696 in human) . This 
molecular event is protein kinase A 
(PKA)-dependent and may be important 
to GDNF-induced lamellipodia formation 
through Rac activation (Fukuda et al., 
2002). Serine/threonine phosphorylation 
by protein kinase C in the juxtamembrane 
regions of EGFR and Met suppresses 
tyrosine phosphorylation (Gandino et al., 
1990; Hunter et al., 1984). However, it is 
unlikely that the juxtamembrane region 
of RET plays an autoinhibitory role 
(Hubbard, 2004; Knowles et al., 2006).
RET-deficient mice, similarly to 
GDNF- and GFR?-de? cient mice (Moore 
et al., 1996; Pichel et al., 1996; Sánchez 
et al., 1996), die at birth due to the renal 
agenesis and severe hypodysplasia 
(Schuchardt et al., 1994). Enteric nervous 
system is also severely impaired in mice 
lacking RET - neurons fail to innervate 
the gut below stomach (Taraviras et al., 
1999). The conditional ablation of GFR?1
in enteric neurons also leads to the defects 
in enteric innervation (Uesaka et al., 
2007). The defects were also found in the 
sympathetic and parasympathetic neurons 
in the absence of GDNF signaling via RET 
(Enomoto et al., 2001; Enomoto et al., 
2000). In the CNS, loss of motoneurons 
was observed when RET was deleted 
(Oppenheim et al., 2000). 
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A study by Kramer and co-authors 
(2007) on conditional RET knockout in the 
CNS and in dopaminergic neurons suggest 
age-dependent loss of these neurons. The 
effect was signi? cant in one year old mice 
and further manifested itself during aging. 
An earlier study performed in younger 
animals that also lack RET gene in 
dopamine neurons reported no phenotype 
(Jain et al., 2006b). A recent study has also 
indicated the significance of GDNF for 
the maintenance of dopaminergic neurons 
(Pascual et al., 2008). 
Lipid rafts and their role in GDNF 
signaling
As GFR?1 is a GPI-anchored protein, it 
is located in lipid rafts. The de? nition of 
lipid rafts is as follows: “Small (10–200 
nm), heterogeneous, highly dynamic,
sterol- and sphingolipid-enriched domains 
that compartmentalize cellular processes 
at the cell membrane. Small rafts can 
sometimes be stabilized to form large 
platforms through protein-protein and 
protein-lipid interactions” (Pike, 2006). 
Although the methods to study lipid 
rafts and the concept itself were heavily 
criticized (Munro, 2003; Shaw, 2006) it 
remains important for understanding of 
many biological phenomena (Simons and 
Toomre, 2000).
Lipid rafts contain many signaling 
molecules. Some of them, for example 
Src kinases or adaptor protein FRS2, 
are covalently linked to the cytoplasmic 
leaf of the raft, which is enriched in 
phospholipids. There is increasing 
evidence that lipid microenvironment 
is crucial for GFLs signaling (reviewed 
by Saarma, 2001; Paratcha and Ibáñez, 
2002). Unliganded RET is located 
outside lipid rafts. GFR?1-mediated RET 
activation by GDNF brings RET to lipid 
rafts where signaling occurs (Tansey et al., 
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2000). It is possible that unliganded RET 
localization outside the lipid rafts is one 
of the mechanisms to prevent signaling of 
the spontaneous RET dimers.
Oligomerization of other GPI-
anchored proteins by antibodies or ligands 
leads to Src family kinases activation, 
resulting in the transmembrane-receptor-
independent signaling (Stefanova et al., 
1991). A plausible mechanism is protein 
oligomerization-driven clusterization of 
distinct lipids rafts followed by trans-
activation of Src kinases. A similar process 
might contribute to RET-independent 
GDNF-induced Src activation through 
GFR?1 (Trupp et al., 1999; Poteryaev et 
al., 1999).
GDNF binding to soluble GFR?1 also 
triggers RET recruitment to lipid rafts. 
The exact mechanism of this phenomenon 
is not fully understood but it requires RET 
tyrosine kinase activity (Paratcha et al., 
2001). Paratcha and coworkers (2001) also 
demonstrated that GFR?1 can be released 
by Schwann cells and neurons.  They 
showed that sciatic nerve lesion leads to 
release of GFR?1.
These ? ndings may help to rationalize 
the fact that GFR?1 is often expressed in 
the absence of RET (Trupp et al., 1997; 
Yu et al., 1998). According to models 
proposed by Paratcha et al. the free GDNF 
and GFR?1 can diffuse over long distances 
to RET-expressing cells. Whereas, GPI-
anchored GFR?1 can present GDNF only 
to neighboring RET expressing cells (this 
transactivation needs a direct contact 
between cells). 
In vitro, soluble and extracellular 
matr ix (ECM)-associated GFR?1
potentiates intracellular signaling, neurite 
outgrowth and neuronal survival. In vivo,
the relevance of this type of signaling 
maybe restricted to CNS (Enomoto et al., 
2004; Canty et al., 2009).
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RET as a dependence receptor
An emerging theme in the growth factor 
receptors biology is the concept of 
“dependence receptors”. Activation of 
the dependence receptor by its ligand 
promotes cell survival while death may be 
actively promoted by the same receptor in 
the absence of ligand (Tauszig-Delamasure 
et al., 2007). Several receptors including 
deleted in colorectal cancer (DCC), 
Netrin-1 receptor UNC5H2 and TrkC act as 
dependence receptors (Forcet et al., 2001; 
Llambi et al., 2005; Tauszig-Delamasure 
et al., 2007). When unliganded, RET also 
triggers cell death when overexpressed in 
some cell lines, and this effect is blocked 
by GDNF (Bordeaux et al., 2000). The 
mechanism is likely to include caspase-
mediated cleavage of a cytoplasmic 
fragment of RET. This fragment appears 
to have pro-apoptotic activity because 
it alone is suf? cient to trigger apoptosis 
(Bordeaux et al., 2000). 
The hypothesis of RET as a 
dependence receptor is supported by the 
analysis of somatotrophs from pituitary of 
RET knockout animals and cell cultures 
(Cañibano et al., 2007). This study 
revealed that in RET-deficient mice the 
adenopituitary was larger than normal 
with somatotroph hyperplasia. In vivo
transduction of RET into pituitary reduced 
the manifestation of this phenotype.
In GDNF-deprived sympathetic and 
dopaminergic neurons, RET is likely 
to induce cell death via a novel non-
mitochondrial pathway (Yu et al., 2003; 
Yu et al., 2008). Overexpression of the 
pro-apoptotic RET fragment did not cause 
death of sympathetic neurons. Yu and 
colleagues, therefore, reasoned that RET, 
similarly to DCC receptor (Forcet et al., 
2001), may be able to recruit and activate 
caspases directly. However, to reveal the 
physiological relevance of this concept the 
development of knock-in mouse models 
with mutated putative caspase cleavage 
sites would be required.
1.4. RET in disease
Chromosomal aberrations and point-
mutations in RET cause a large portion 
(up to 61%) of papillary thyroid cancers 
(Thomas et al., 1999), the majority of 
medullary thyroid carcinomas and all 
multiple endocrine neoplasia type 2 
(Hofstra et al., 1994).  Abnormalities 
in RET gene are especially common in 
patients with pediatric thyroid cancers 
(Nikiforov et al., 1997) but are also 
responsible for up to 43 % of adult cases 
(Lam et al., 1998).
Somatic rearrangements of RET
gene can occur as a result of ionizing 
radiation and because thyroid follicular 
cells accumulate [131]-iodine (Santoro et al., 
2000), which is the ? rst stable isotope of 
uranium decay. Up to 57% of children who 
suffered from thyroid cancer as a result of 
Chernobyl disaster had a papillary thyroid 
carcinoma (PTC). In these cases RET 
tyrosine kinase domain was fused with 
5’-terminal regions of heterologous genes 
(Fugazzola et al., 1995; Ito et al., 1994), 
generating chimeric oncogene designated 
as RET/PTC. RET normally is not 
expressed by thyroid follicular cells but 
in the case of RET/PTC the expression is 
driven by promoter of the fused gene. The 
fusion partner, which may be considered 
as an activating element, usually lacks 
signal peptide to deliver the RET/PTC 
chimera to the plasma membrane but the 
activating element contains a dimerization 
motif (Santoro et al., 2002). Thus, this 
fusion protein induces ligand-independent 
RET kinase activation in the cytoplasm. 
Gain-of-function germline missense 
mutations in RET  cause MEN2A 
and MEN2B syndrome and familial 
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medullary thyroid carcinoma (FMTC). 
Molecular signature of MEN2A syndrome 
has already been discussed earlier in 
this text. MEN2B-RET is activated 
independently of ligand and does not 
require dimerization. MEN2B syndrome 
is characterized by the most aggressive 
disease progression, the earliest onset and 
the worst prognosis among the patients 
with RET mutations. Majority of MEN2B 
cases are caused by single substitution 
of methionine-918 with threonine in the 
kinase domain of RET (Carlson et al., 
1994) (Fig. 4C). Substitution of alanine 
883 to phenylalanine also causes MEN2B 
(Smith et al., 1997). Double mutations 
Val804Met/Val804Met and Val804Met/
Ser904Cys are involved in MEN2B as 
well (Menko et al., 2002; Miyauchi et al., 
1999).
The residue corresponding to 
methionine 918 is highly conserved in 
all receptor tyrosine kinases, whereas 
cytoplasmic protein tyrosine kinases have 
a threonine in this position. This residue 
is predicted to alter the substrate selection, 
as it was mapped to the substrate binding 
pocket (Pandit et al., 1996; Songyang 
et al., 1995). Indeed, substitution of 
bulky methionine with smaller and polar 
threonine may result in tighter substrate 
binding and increased catalytic activity 
(Fig. 4C).
However,  the model of  RET 
inhibition in trans (Knowles et al., 2006) 
suggests that Met918 may be a hot-spot 
of inhibitory dimer formation, which 
efficiently blocks ATP- and substrate-
binding pockets. The substitution with 
threonine in position 918 would result 
in kinase dimer destabilization and thus 
kinase activation.
Similarly, two transforming mutations, 
P766S and E768D/A919P (Iwashita et 
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al., 2000; Santoro et al., 2004), are at the 
dimer interface (Knowles et a., 2006).
The MEN2B mutations lead to a 
qualitatively distinct from wild type RET 
signaling, as revealed by phosphopeptide 
mapping analysis (Liu et al., 1996). The 
pattern of phosphorylated intracellular 
proteins is also different  (Murakami et al., 
1999; Santoro et al., 1995).
FMTC-causing mutations in the 
kinase domain of RET include Glu768Asp, 
Leu790Phe, Tyr791Phe, Val804Leu/
Met, Ser891Ala and a double mutation 
Val778Ile/Val804Cys (reviewed by 
Ichihara et al., 2004). Some somatic RET
mutations may cause sporadic medullary 
carcinoma. The molecular mechanisms 
underlying RET activation by these 
mutations are poorly understood. 
In addition to gain-of-function 
mutations, loss-of-function mutations of 
RET exist. RET is abundantly expressed 
in neuronal progenitors of the vagal, trunk 
and sacral neural crest cells (Pachnis et 
al., 1993), which give rise to ENS and 
are important to the formation of ENS. 
Loss-of-function mutations in RET
cause Hirschsprung’s disease (HSCR), 
which is characterized by megacolon 
with aganglionosis (Parisi and Kapur, 
2000). The management of the disease 
currently requires operational removal of 
aganglionic segment of colon.
HSCR mutations in RET are divided 
into four classes. Class I mutations are 
in the ECD. These mutations appear 
to interfere with RET maturation and 
inhibit its translocation to the plasma 
membrane (Carlomagno et al., 1996). 
Class II mutations cause the substitution 
of the cysteine residues in the cysteine-
rich domain (Cys609, 611, 618, and 620). 
Paradoxically, these mutations are also 
responsible for MEN2A and FMTC, which 
involve constitutively active forms of RET. 
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Furthermore, in some individuals MEN2A/
FMTC coincides with HSCR (Takahashi 
et al., 1999). This could be explained by 
the fact that the HSCR-RET residing in 
the endoplasmic reticulum cannot respond 
to GDNF and guide neurons along GDNF 
gradient, but its oncogenic potential is 
nevertheless realized in the cytoplasm 
(Runeberg-Roos et al., 2007). Class 
III mutations affect the tyrosine kinase 
domain and suppress its catalytic activity. 
Class IV mutations speci? cally interfere 
with the binding of the adaptor proteins to 
activated RET (Iwashita et al., 2001).
O n e  m a y  e n v i s a g e  t h a t 
pharmaceuticals enhancing protein 
folding (i.e. chemical chaperones) may 
help patients with HSCR type I and type 
II mutations. Conversely,   tyrosine kinase 
inhibitors like Gleevec inhibit cell growth 
and RET kinase activity in vitro (Cohen 
et al., 2002). The pyrazolo-pyrimidine 
PP1 blocks tumorigenesis induced by 
RET/PTC (Carlomagno et al., 2002a). 
Another pyrazolo-pyrimidine PP2 and 
the 4-anilinoquinazoline are inhibitory to 
oncogenic RET kinases (Carlomagno et 
al., 2002b; 2003). These two pyrazolo-
pyrimidines are, however, not clinically 
relevant because of unspeci? city.
One phase II clinical trial was recently 
completed with Sorafenib (multi-kinase 
inhibitor targeting RET, PDGFR, VEGFR 
and Raf) demonstrating its effectiveness 
in advanced thyroid cancer (Gupta-
Abramson et al., 2008). Another drug 
XL184 is under intense clinical study and 
ZD6474 (Zactima) may also result in an 
improvement of advanced thyroid cancer 
management (www.ClinicalTrials.gov)
In addition, a novel class of inhibitory 
macromolecules has been developed. 
These molecules are known as aptamers 
(speci? c oligonucleotide ligands) that were 
selected by in vitro evolution technology 
(Cerchia et al., 2005). The neutralizing 
aptamers obtained in this study interfere 
with the MEN2A mutation-induced 
RET dimerization and thus prevent its 
activation.
1.5. RET-independent GFLs signaling
Evidence for RET-independent GFLs 
signaling
The widespread expression of GFR?1
in the absence of RET suggests that 
alternative GFLs receptor may exist. In 
the brain GFR?1 is expressed in certain 
RET-lacking areas like forebrain, cortex 
and hippocampus (Trupp et al., 1997; Yu 
et al., 1998). GFR?1 is expressed also in 
the inner ear, where RET is not (Ylikoski 
et al., 1998). Being an extracellular GPI-
anchored protein, GFR?1 may evoke 
intracellular signaling directly (Stefanova 
et al., 1991; Ledda et al., 2007) but, in most 
cases, GFR?1 requires a transmembrane 
receptor to mediate GDNF-induced 
signal.
RET-independent signaling was 
discovered in cell lines and neurons 
deficient in RET (Trupp et al., 1999; 
Poteryaev et al., 1999). GDNF can 
rapidly induce Src-family kinases (SFK) 
activation in GFR?1-dependent manner. 
GDNF also robustly activates MAPK and 
PLC? leading to CREB phosphorylation. 
Furthermore, in kidney explants from 
RET-deficient mice GDNF increased 
branching morphogenesis through Src 
kinase-dependent activation of the 
receptor tyrosine kinase MET. Activation 
of MET by GDNF is likely to occur via 
intracellular signaling circuit, for direct 
interaction between GDNF and MET was 
not detected (Popsueva et al., 2003). In 
addition, GDNF activates rat peritoneal 
macrophages in a RET-independent 
manner (Hashimoto et al., 2005).
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GDNF can, in the absence of RET, 
induce homophilic interaction between 
two GFR?1 molecules located on opposed 
synaptic termini (Ledda et al., 2007). This 
trans-interaction leads to precise spatial 
presynaptic differentiation and was termed 
ligand-induced cell adhesion.
Chao and col leagues  (2003) 
demonstrated that GDNF can upregulate 
the expression of NCAM and ?v integrin 
subunit in rat midbrain dopaminergic 
neurons. Function-blocking antibodies 
against NCAM and ?v integrin inhibited 
GDNF-induced survival and neurite 
outgrowth. Authors therefore proposed that 
?v integrin and NCAM mediate effects 
of GDNF. Another report suggested that 
GDNF can signal via ?1 integrin  (Cao et 
al., 2008).
Neural cell adhesion molecule is an 
alternative GFL receptor
The study highlighting the role of NCAM 
in GDNF-induced signaling was carried 
out by Paratcha and coworkers (2003). 
NCAM is a cell adhesion molecule in the 
nervous system (Rutishauser et al., 1988) 
that promotes cell adhesion and migration, 
neurite outgrowth, synaptogenesis and 
regulates synaptic plasticity (Fields and 
Itoh, 1996; Schachner, 1997). NCAM 
is highly expressed in many developing 
tissues and, in particular, it localizes in 
the nerve growth cone (van den Pol et 
al., 1986). Hence, NCAM is thought to 
play a role in the development of nervous 
system.
The regulation of these developmental 
processes is mediated mostly by 
homophilic interaction of NCAM. It 
belongs to immunoglobulin superfamily 
with its ? ve Ig-like extracellular domains. 
Homophilic interaction occurs between 
NCAM Ig-domain 3 on apposing cells 
(Rao et al., 1993). This interaction may 
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result in the activation of cytoplasmic 
signaling molecules associated with 
NCAM (Maness et al., 1996). 
Isoforms of 180, 140 and 120 kD 
result from alternative mRNA splicing. 
Isoforms 180 and 140 are single-pass 
transmembrane proteins, whereas 120 
kD isoform is a GPI-anchored protein 
lacking cytoplasmic domain. By virtue of 
its GPI anchor isoform, 120 is located in 
the lipid rafts. Other NCAM isoforms are 
also likely to be located in the lipid rafts 
due to palmitoylation, which is crucial for 
NCAM-induced signaling. A negatively 
charged glycan, the polysialic acid (PSA), 
is associated with NCAM (Finne et al., 
1983). In vitro studies on puri? ed PSA-
NCAM demonstrated that PSA decreases 
homophilic NCAM-mediated interaction. 
It is therefore considered to be the anti-
adhesive component of NCAM molecule 
that promotes migration (Kleene and 
Schachner, 2004).
The cytoplasmic domain of NCAM 
is constitutively associated with a SFK 
Fyn. Fyn becomes rapidly and transiently 
activated upon NCAM homophilic 
oligomerization (Beggs et al., 1997). This 
leads to the cytoskeletal rearrangements 
including neurite outgrowth and cell 
migration. NCAM can also transactivate 
the fibroblast growth factor (FGF) 
receptor (Saffell et al., 1997). NCAM 
contains a heparin binding pocket and 
therefore interacts with heparan sulfate 
proteoglycans (HSPGs) (Storms and 
Rutishauser, 1998), the family of proteins 
that includes transmembrane receptors 
modulating various cellular processes 
(see below). In addition, PSA-NCAM 
modulates the activity of neurotrophic 
factors. BDNF is accumulated by PSA-
NCAM and presented to the BDNF 
receptor TrkB, thus enhancing biological 
activity of BDNF for survival and 
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complex possibly exists. The impairment 
of cell-cell adhesion hinted that cellular 
migration, especially when cells use other 
cells as a substrate to move (known as 
chain migration), may be enhanced when 
NCAM-NCAM homophilic interaction 
is inhibited. Indeed, the migration of 
Schwann cells, expressing both GFR?1
and NCAM, from explants of rat sciatic 
nerve was greatly enhanced when 
explants were grown on the fibroblasts 
overexpressing GDNF. Other biological 
effects elicited by GDNF-NCAM signaling 
pathway include axonal growth of cortical 
and hippocampal neurons, when plated on 
immobilized GDNF. Importantly, soluble 
GDNF is ineffective inducer of neurite 
outgrowth. These ? ndings suggest distinct 
signaling pathways to modulate short- 
and long-range (via RET) intercellular 
communication (Sariola and Saarma, 
2003; Paratcha et al., 2006a)
Migration-promoting (or cell-cell 
adhesion-inhibiting) effects of GFR?1/
NCAM complex have implications in 
vivo. In GFR?1-de? cient mice, there is a 
characteristic widening of RMS similarly 
to NCAM-de? cient mice. 
In addition, adult heterozygous 
GDNF-deficient mice have impaired 
spatial learning similar to the NCAM 
mutants (Cremer et al., 1994; Gerlai et al., 
2001). These results indicate that GDNF 
and GFR?1 can regulate neuronal synaptic 
plasticity through NCAM in the adult 
brain. The cross-talk between NCAM and 
RET may result from GDNF stimulation of 
the cell where both receptors are present. 
For example, NCAM function-blocking 
antibodies inhibited GDNF survival 
promoting effect in midbrain dopaminergic 
neurons, in which RET and GFR?1 are 
also present (Chao et al., 2003).
As NCAM and RET are not 
expressed in the developing brain cortex, 
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differentiation of neurons, presumably by 
increasing local concentration of BDNF 
in the vicinity of TrkB (Vutskits et al., 
2001).
NCAM-de? cient mice are viable and 
fertile (Cremer et al., 1994). The reported 
phenotypes include deficits in neuronal 
migration and synaptic organization, as 
well as marked impairment in synaptic 
plasticity, spatial learning and long-term 
potentiation (LTP). The most distinctive 
abnormality in the CNS of these mice is a 
reduction of the size of the olfactory bulbs 
(Cremer et al., 1994). This is caused by 
migratory de? cits of neuronal precursors 
in the rostral migratory stream (RMS). 
This pathway directs cell migration from 
subventricular zone to the olfactory 
bulb. PSA-NCAM is expressed along 
entire RMS and is important for neuronal 
migration towards olfactory bulb. In the 
absence of NCAM cells accumulate in 
the RMS thus widening it (Paratcha et al., 
2003).
GDNF binds to NCAM in the 
presence of GFR?1 with high affinity 
(Kd ~1nM). GDNF also interacts with 
NCAM alone, although with lower 
affinity (Kd ~5nM) (Paratcha et al., 
2003). Downstream signaling pathways 
associated with NCAM could be activated 
in non-homophilic manner. GDNF was 
demonstrated to potently activate Fyn 
through GFR?1/NCAM receptor complex. 
Cell-cell adhesion mediated by homophilic 
interaction of NCAM was impaired in the 
presence of GFR?1, further supporting 
the hypothesis of functional complex 
formation between NCAM and GFR?1. 
Interestingly, the inhibition of cell-
cell adhesion was impaired even in the 
absence of ligand when both NCAM 
and GFR?1 were overexpressed. This 
suggests that, similarly to GFR?1/RET, 
functional preformed GFR?1/NCAM 
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the ? nding that GDNF promotes migration 
of cortical GABAergic neuronal precursors 
(Pozas and Ibáñez, 2005) suggests the 
notion that additional receptors for GDNF 
exist. Another study further confirmed 
this, as mice manipulated to express RET 
and GFR?1 under the same promoter 
(Enomoto et al., 2004) exhibit a loss of 
GABAergic cells in the cortex (Canty et 
al., 2009).
1.6. Heparan sulfate proteoglycans
As communication between cells is of 
crucial importance for multicellular 
organisms, the environment for this 
interaction, i.e. the ECM, must be 
considered. The long range communication 
between cells requires the messenger 
molecules to be released, diffused and 
docked to the receptors on the target cell. 
The ECM can modulate all of these steps 
(Geiger et al., 2001; Hynes, 1999; Juliano, 
2002).
ECM mostly consists of fibrillar 
proteins, polymerized sugars and proteins 
that present them. ECM provides spatial 
clues and a scaffold for the cellular 
adhesion and migration (Couchman, 
2003). Although, these processes generally 
rely on the major ECM components, for 
many fine-tuned biological processes 
matrix-associated proteins are required. 
These proteins have an af? nity to major 
ECM components and are expressed only 
transiently and/or locally (Kinnunen et al., 
1996; Taipale et al., 1994). 
Sugar components of the ECM are 
mostly glycosaminoglycans (GAGs). 
They are long, repeating, linear polymers 
of disaccharides. Usually, one sugar is a 
glucuronic acid or its epimer iduronic acid, 
and the other is either N-acetylglucosamine 
or N-acetylgalactosamine (Bishop et 
al., 2007). GAGs are negatively charged 
carbohydrates due to their sulfate 
component. Therefore, GAGs may serve as 
a binding site for many matrix-associated 
proteins.
Proteoglycans that carry GAGs show 
considerable diversity, with variations in 
the protein core identity and structure. 
Nevertheless, the biochemical and 
biological properties of proteoglycans are 
dominated by their sugar components. 
Despite of the seemingly low complexity 
of GAGs’ constituents, the diversity 
created by the differences in epimerization 
and sulfation of these carbohydrate 
polymers can be huge (Bernfield et al., 
1999). Notably, the epimerisation and 
sulfation signature of the GAGs can be 
unique for certain cells and can vary in the 
same cells during development. 
There are several major classes of 
GAGs in the ECM: heparan sulfates 
(presented by ECD of syndecans, 
g lypicans ,  per lecan  and  agr in) ,  
chondroitin sulfates (by syndecans, 
decorin and aggrecan), dermatan sulfates 
(by betaglycan) and keratan sulfates (by 
aggrecan) (Alberts, 2002). 
Many of the matrix-associated 
proteins are growth factors that bind to 
one of the key ECM components, heparan 
sulfates (HS) (Bernfield et al., 1999; 
Esko and Selleck, 2002). This interaction 
modulates growth factors’ diffusion and 
binding to their receptors. Binding of 
some proteins to HS results in direct 
activation of signaling pathways induced 
by receptors bearing HS (Bass et al., 2007; 
Rauvala et al., 2000)
 HS are presented by HSPGs. HSPGs 
can reside in ECM (perlecan, agrin 
and others) or be associated with cell 
plasma membrane (syndecans, glypicans, 
betaglycan, CD44v3) (Bishop et al., 2007). 
Glypicans are GPI-anchored proteins that 
lack transmembrane and intracellular 
domains and are unable to relay GF 
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signaling. Syndecans represent the type I 
class of transmembrane proteins (Fig. 5). 
HSPGs were ? rst brought into light 
by the discovery that HS chains are 
necessary for FGF signaling (Rapraeger 
et al., 1991; Yayon et al., 1991). FGFs are 
unable to activate their receptors (FGFR) 
in the absence of HS.  Disruption of this 
interaction leads to drastic developmental 
consequences (García-García and 
Anderson, 2003). 
Soon after the discovery of the HS 
requirement for FGFR activation, evidence 
from Drosophila melanogaster genetic 
screens suggested the involvement of 
HSPGs in the regulation of Wnt and Indian 
Hedgehog (Hh) pathways. Phenotypes 
of the mutations that affect embryonic 
segment polarity are strikingly similar to 
the phenotypes of those with mutations in 
the components of Wnt and Hh signaling 
pathways. Five genes were identified: 
sugarless (sgl), sulfateless (s?), tout velu 
(ttv), fringe connection (frc) and slalom 
(sll). All of these genes were subsequently 
found to encode enzymes or nucleotide 
sugar transporters that are involved in 
GAG biosynthesis (reviewed by Häcker et 
al., 2005).
HSPGs are present on the surface of 
every eukaryotic cell (Sasisekharan et al., 
2002), except certain lymphoblastoma cell 
lines (Lebakken and Rapraeger, 1996). 
HSPGs are generally more abundant at the 
cell surface than most receptors (Bern? eld 
et al., 1999). Despite of high abundance, 
the interaction between GF and HS chains 
of syndecan can be very specific, in 
“lock-and-key” fashion, and tight (Bourin 
and Lindahl, 1993). Interactions are 
Fig. 5. Homology model of syndecan-3. Heparan sulfate (HS) chains are shown as stick models. 
HS are attached to the serines in the Ser-Gly/Ala dipeptide sequences. Extracellular domain of 
syndecan was modeled by HHpred using invasin structure as a template. Intracellular domain was 
modeled on the basis of syndecan-4 cytoplasmic domain NMR structure.
HS
Cytoplasmic
domain
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characterized by relatively low Kd values, 
ranging from 1nM to 100nM (Bern? eld 
et al., 1999). Remarkably, interaction 
of certain GFLs with their high-affinity 
receptors also falls into this range (Cik et 
al., 2000).
The tissue-specific expression of 
individual proteoglycan core proteins will 
obviously determine when and where HS 
are expressed. It is important to stress 
that ligand binding by proteoglycans 
depends on the structure of their HS 
chains. Different extent of sulfation 
of disaccharides and epimerization of 
glucuronic acid can theoretically yield 
as many as 48 different disaccharides. 
However, only 23 disaccharides have been 
identi? ed (Esko and Selleck, 2002), which 
is still a greater number than 20 naturally 
occurring amino acids. The structure 
of the HS chains ultimately depends 
on the regulated activity of multiple 
glycosyltransferases, sulfotransferases 
and an epimerase (Esko and Lindahl, 
2001). These enzymes are arrayed in the 
lumen of the Golgi apparatus. A series 
of cytoplasmic enzymes are needed 
to catalyze the nucleotide-sugar and 
nucleotide-sulfate formation, which are 
actual substrates for the transferases. 
Surprisingly, the general organization of 
HS rather than their ? ne structure appears 
to determine the speci? city of HS-protein 
interactions (Kreuger et al., 2006).
The biosynthesis of GAGs chains 
starts with the addition of xylose to serine 
residues in the core protein and proceeds 
by stepwise addition of two galactose 
residues and one glucuronic acid (Bishop 
et al., 2007). Alternating addition of 
N-acetylglucosamine and glucuronic 
acid leads to formation of the HS. The 
polymerization is accompanied by limited 
epimerization of glucuronic acid to iduronic 
acid (at C-5 position of the sugar) and by 
sulfation of the disaccharides at different 
positions (Fig. 6). Sulfation can occur at 
2-O position in glucuronic or iduronic 
acid. Acetyl in N-acetylglucosamine can 
be substituted with sulfate. In addition, 
sulfation at 2-O, 3-O and 6-O positions of 
N-acetylglucosamine can take place (Esko 
and Selleck, 2002).
Defects in the HS biosynthesis are 
devastating to the developing organism. 
The mutation in one of the crucial 
enzymes for HS biosynthesis in mice, 
UDP-glucose dehydrogenase, results in 
embryos arrest during gastrulation because 
of the failure of mesodermal migration 
(García-García and Anderson, 2003). 
FGF8 knockout mice have very similar 
phenotype (Sun et al., 1999). Dysfunction 
of  copolymerase EXT1, the enzyme that 
catalyzes HS polymerization, leads to the 
disruption of gastrulation and embryonic 
lethality before embryonic day 8.5 (E8.5). 
In EXT1-/- embryos Indian Hedgehog (Hh) 
fails to bind to appropriate target cells (Lin 
et al., 2000). Neural-speci? c conditional 
knockout of EXT1 showed that EXT1 
is crucial for brain patterning and axon 
scaffold formation in the forebrain (Inatani 
et al., 2003). The mutation in enzyme 
2-O-sulfotransferase, which is important 
for disaccharides’ sulfation, leads to renal 
agenesis in mice (Bullock et al., 1998). 
This defect in HS synthesis may affect 
many signaling pathways including Wnt, 
Hh and GDNF signaling. Furthermore, 
targeted disruption of a murine glucuronyl 
C5-epimerase gene results in kidney 
agenesis, lung and skeletal defects (Li 
et al., 2003). Similarly, mice de? cient in 
N-deacetylase/N-sulfotransferase isoform 
1 show immature lungs and severe skeletal 
abnormalities (Ringvall et al., 2000). 
These mice also exhibit forebrain and 
eye defects, cerebral hypoplasia and the 
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olfactory bulbs are absent (Grobe et al., 
2005).
Mice  de f i c i en t  i n  t he  6 -O 
-sulfotransferases SULF1 and SULF2 
have defects in the esophagus innervation 
(Ai et al., 2007). 
Syndecans
The founding member of syndecan family 
of transmembrane HSPGs – syndecan-1 
was discovered by Rapraeger and 
Bern? eld (1983) in mammary epithelial 
cells.  To date four syndecans have been 
characterized in vertebrates. The syndecan 
family includes: syndecan-1, syndecan-2 
(also known as fibroglycan) (Marynen 
et al., 1989), syndecan-3 (N-syndecan) 
(Carey et al., 1992; Gould et al., 1992) and 
syndecan-4 (ryudocan or amphiglycan) 
(David et al., 1992; Kojima et al., 1992). 
Syndecan-1 is mostly expressed by 
epithelia. Syndecan-2 is abundant in 
mesenchymal tissues, liver and neuronal 
cells. Syndecan-3 is mostly neuronal. 
Syndecan-4 is ubiquitously expressed 
(Bern? eld et al., 1999). Most cells express 
at least one member of the syndecan 
family (Lebakken and Rapraeger, 1996). 
However, many cells express two or more 
syndecans, suggesting that each syndecan 
may have specific functions at the cell 
surface (Kim et al., 1994).
The unifying features of the syndecan 
family, in addition to the presence of 
HS chains, are their highly conserved 
transmembrane and cytoplasmic domains. 
Intracellular domains of syndecans interact 
with many adaptor proteins that have an 
effect on actin dynamics thus driving cell 
adhesion and migration, neurite outgrowth 
and synapse formation (Couchman, 
2003). In contrast, their ECDs are very 
divergent with the exception of HS chains 
attachment.
Syndecans are shown to “function 
as membrane receptors for a bewildering 
array of ligands” (Couchman, 2003). 
The growing list of proteins interacting 
with syndecans includes growth factors 
(TGF?1&2; FGFs; VEGF; IGF-II, PDGF-
AA; EGF family; among others), GF 
binding proteins (TGF?-BP; follistatin; 
IGF-BP), morphogens (activin; BMPs; 
chordin; Dpp; Hh; Sprouty and Wnts), 
cytokines (ILs, GM-CSF; Interferon-?;
TNF-?), ECM components (Heparin-
binding growth associated molecule (HB-
GAM/pleiotrophin), ? bronectin, laminins, 
tenascin, thrombospondin, vitronectin 
and collagen), cell adhesion molecules 
(NCAM, L-selectin, PECAM-1) and many 
others (Bern? eld et al., 1999; Bishop et 
al., 2007).
Fig. 6. The structure of a major 
heparan sulfates building block, the 
disaccharide glucuronic acid (GlcA)/
N-acetylg lucosamine (GlcNAc) . 
Epimerisation at position C-5 (5) of GlcA 
results in iduronic acid.  N-sulfation 
occurs when acetyl in GlcNAc is 
substituted with sulfate. 2-O-sulfatation 
occurs in both GlcA and GlcNAc. 
However, 3-O-sulfatation and sulfatation 
in 6-O-position was observed only in 
GlcNAc.
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Role of HSPGs in GDNF-signaling?
GDNF was originally puri? ed by heparin–
af? nity chromatography (Lin et al., 1993) 
and later its interaction with heparan 
sulfates was documented (Rickard et 
al., 2003). Heparan sulfates appear to 
be required for the GDNF signaling 
via GFR? and RET (Sainio et al., 1997; 
Tanaka et al., 2002; Barnett et al., 2002). 
Thus, syndecans may act as a co-receptors 
for GFR?1/RET receptor complex.
 Barnett and colleagues (2002) 
demonstrated that in HS-deficient cells 
GDNF fails to efficiently induce RET 
phosphorylation. This results in the 
reduced biological activity of GDNF 
leading to impaired GDNF-induced neurite 
outgrowth from dorsal root ganglion 
neurons and tubulogenesis failure by 
epithelial kidney cells. 
However, the molecular identity of 
GDNF binding ECM components was not 
revealed in these studies. Later, the HSPG 
agrin located in ECM was suggested to 
interact with GDNF (Iwase et al., 2005).
Interaction with HS leads to obstructed 
diffusion of the exogenous GFLs from 
the injection site in the brain. This could 
exert adverse effects in Parkinson’s 
disease therapies utilizing GDNF or 
NRTN. Coinfusion of GFLs with heparin 
drastically increases GDNF, NRTN and 
ARTN biodistribution (Hamilton et 
al., 2001). In addition, mutated GDNF 
lacking its heparin-binding determinants 
on N-terminus (Alfano et al., 2007) 
diffuses more ef? ciently than its wild-type 
counterpart (Piltonen et al., 2009). This 
may have implications in the development 
of new GFL-based protein drugs against 
neurodegenerative diseases.
Syndecans mainly serve as low-
af? nity but high-capacity co-receptors for 
a variety of signal-transducing receptors. 
Binding to syndecan leads to ligand 
immobilization on the plasma membrane, 
which facilitates ligand binding to its 
primary receptor (Derksen et al., 2002). 
Localization of syndecans to specific 
membrane compartments, such as focal 
adhesions, sequesters ligands in the 
vicinity of their high-affinity receptors 
that are localized to the same structures. 
The distribution of syndecans on the cell 
surface is dictated in part by association 
with the cytoskeleton via their cytoplasmic 
domains (Carey, 1997). 
As discussed above, syndecans 
being a HSPG provide HS chains for the 
stabilization of the FGF-FGFR complex. 
In addition, syndecans interact with 
NCAM (Storms and Rutishauser, 1998), a 
cell adhesion molecule and an alternative 
receptor for GDNF (Paratcha et al., 2003). 
ECD of NCAM contains a heparin-
binding site in its second Ig-like domain 
(Cole and Glaser, 1986; Cole et al., 1986). 
It may interact with HSPG in the ECM, 
and with syndecans expressed on the same 
or on apposing cells. Therefore, syndecans 
may modulate the NCAM homophilic 
interaction or NCAM/GFR?1-mediated 
GDNF signaling.
Syndecans are also thought to 
modulate the activity of the axon 
guidance receptors: Robo, DCC and Eph. 
The modulation is likely to occur via 
interaction of the ECD of these receptors 
and HS chains of the syndecans (reviewed 
by Lee and Chien, 2005).
 Syndecans also modulate the activity 
of integrins (Morgan et al., 2007). Cell 
attachment and spreading appears to 
be integrin-mediated, whereas later 
cytoskeletal rearrangement required 
for full spreading is likely to be HSPG-
mediated (Gallagher, 1997). Syndecans 
cooperatively with integrins bind to 
the same ECM substrate but to discrete 
structural domains of the protein. For 
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instance, ? bronectin contains a heparin-
binding motif in one domain and the Arg-
Gly-Asp (RGD) sequence, which is known 
to activate integrins, in another domain. 
It was also proposed that syndecans, via 
their HS chains, may directly modulate the 
integrin interaction with its ligand (Carey, 
1997). However, whether the effect is 
promoted by HS chains or by syndecan 
core protein remains open (Beauvais 
et al., 2004). Affinity modulation of 
some integrins is complex and involves 
conformational changes within its ECD 
(Beglova et al., 2002). This process is 
regulated by “inside-out” signaling that 
affects integrin’s cytoplasmic domain 
either by proteolysis, phosphorylation or 
binding of intracellular proteins such as 
talin (reviewed by Hynes, 2002). These 
intracellular events lead to the exposure of 
the ligand-binding epitopes in integrin’s 
ECD.
As syndecans activate Src family 
kinases (Kinnunen et al., 1998) and 
protein kinase C alpha (PKC?) (Lebakken 
and Rapraeger, 1996; Oh et al., 1998) 
syndecan signaling may consequently 
activate integrins in an inside-out manner. 
Similar “inside-out” signaling may trigger 
syndecan ectodomain shedding (Bass et 
al., 2009).
Syndecans signaling
Syndecans lack intrinsic kinase or 
phosphatase activity but all syndecans 
induce a number of biological effects by 
activating several intracellular signaling 
pathways. The exact mechanism of how 
syndecans activate downstream signaling 
pathways is not known. Some evidence 
advocates that syndecan clustering and/
or oligomerization occurs in several 
ligand-triggered cellular events occurs, 
including the syndecan-4 signaling in 
focal adhesions or HB-GAM-induced 
syndecan-3 activation (Rauvala et al., 
2000).
Molecular mechanisms underlying 
spreading, migration and axon guidance 
involve changes in actin dynamics, and 
intracellular domains of syndecans can 
interact with many cytoskeletal proteins. 
Indeed, syndecan-2 interacts with actin-
binding protein ezrin that regulates many 
aspects of actin assembly (Granés et 
al., 2000). Syndecan-3 activation by its 
ligands leads to Src-kinase activation 
and phosphorylation of cortactin, the 
protein that regulates branching of 
actin filaments (Kinnunen et al., 1998). 
Syndecan-4 is found in focal adhesions 
(Woods and Couchman, 1994), interacts 
with PKC? (Oh et al., 1998) and actin-
bundling protein ?-actinin (Greene et al., 
2003). Syndecan-4 also modulates FAK 
phosphorylation (Wilcox-Adelman et al., 
2002). Syndecan-1 has not been reported 
to interact with cytoskeletal proteins yet. 
However, Syndecan-1 overexpression 
renders floating lymphoblastoid cell 
line adhesive (Lebakken and Rapraeger, 
1996).  Taken together, these facts strongly 
suggest that syndecans can commute 
extracellular signals to the cytoskeleton, 
playing a pivotal role in many ECM-
induced cellular processes.
Syndecan-3 is the only syndecan 
shown to signal independently via SFK 
activation without assistance from other 
receptors (Raulo et al., 1994; Kinnunen et 
al., 1998). The immobilized (but not the 
free) HB-GAM induces via syndecan-3 
neurite outgrowth in rat embryonic 
hippocampal neurons and spreading 
of many cell types (Raulo et al., 1994; 
Kinnunen et al., 1998) 
HB-GAM is  a  non-cova len t 
homodimeric protein. The thrombospondin 
type I repeats in HB-GAM are responsible 
for heparan sulfate binding (Rauvala et al., 
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2000). This protein structure, containing 
two or more heparin binding sites, provides 
a scaffold for syndecan-3 ligation. Indeed, 
it is easy to imagine that a protein with 
several valences for HS chains can induce 
clustering of syndecan while being bound 
to ECM. The syndecan-3 cytoplasmic 
domain is thought to be associated 
directly or via adaptor proteins with SFK. 
Oligomerized syndecan-3 thus may locally 
increase SFK concentration leading to 
transactivation of SFK. Alternatively, 
SFK may bind with higher af? nity to the 
oligomerized receptor. 
Furthermore, syndecan-4 clustering 
induces receptor translocation to lipid 
rafts (Tkachenko and Simons, 2002). 
This ? nding may be extrapolated to other 
syndecans because the translocation is 
likely to be mediated by the EFYA motif 
in the cytoplasmic domain, which is 
absolutely conserved in all syndecans 
(Bernfield et al., 1999). The fact that 
syndecans undergo translocation to the 
lipid rafts upon activation may shed light 
on the mechanisms of HB-GAM-induced 
SFK activation. Syndecans function as 
co-receptors for RTK may also require 
their localization in the rafts, since FGF2 
signaling through FGFR requires HSPG-
mediated FGFR translocation to lipid rafts 
(Chu et al., 2004).
Syndecan-3-de? cient mice are viable 
and fertile. However, they exhibit an 
enhanced level of long-term potentiation 
(LTP) in CA1 region of the hippocampus 
(Kaksonen et al., 2002). Conversely, in HB-
GAM-de? cient mice, a lowered threshold 
for induction of LTP was observed, 
which was restored to the wild-type 
level by application of recombinant HB-
GAM (Amet et al., 2001). Consistently, 
HB-GAM overexpressing mice show 
attenuated LTP. The changes in LTP, are 
accompanied by behavioral alterations. 
These ? ndings pose HB-GAM as the only 
known extracellular macromolecule that 
inhibits LTP and suggest that syndecan-3 
influences synaptic plasticity and 
hippocampus-dependent memory. 
Syndecans in disease
In mammals, feeding behavior is 
controlled by several hypothalamic 
peptides. Antisatiety peptides (e.g. agouti-
related protein, Agrp) enhance feeding 
when introduced into the brain, whereas 
satiety peptides, such as ?-melanocyte 
stimulating hormone (?-MSH), reduce 
feeding. Agrp is an antagonist competing 
with ?-MSH for binding to the common 
G-protein-coupled receptor (GPCR) 
(Woods et al., 1998). Syndecan-3 is 
expressed in hypothalamic feeding 
centers and modulates feeding behavior 
(Reizes et al., 2001). Syndecan-3 via its 
HS chains acts as a co-receptor for Agrp, 
thus increasing af? nity of this antisatiety 
peptide to GPCR. Upon regulated 
cleavage of syndecan-3 ECD from the 
cell-surface, Agrp cannot interact with the 
receptor any longer and ?-MSH can bind 
to GPCR, thus reducing feeding. These 
? ndings allow suggesting that mutations 
of syndecan-3 cleavage site, syndecan-3 
overexpression or missexpression of 
other syndecans in hypothalamus as 
well as defects in proteases responsible 
for syndecan-3 ECD shedding would 
result in changes in feeding behavior and 
subsequently obesityDefects in syndecan-3
gene or HB-GAM signaling may also lead 
to neurological (e.g. memory) disorders 
(Kaksonen et al., 2002; Pavlov et al., 
2002) and developmental defects due to 
impaired neuronal migration (Hienola et 
al., 2006).
Syndecan-1- and syndecan-4-null 
mice do not have obvious developmental 
defects, and are fertile. However, when 
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challenged by wounding, their skin 
regeneration is slow (Alexopoulou et 
al., 2007).  In syndecan-1-de? cient mice 
the defect may arise from an impaired 
cell adhesion or GF binding (Stepp et 
al., 2002). Syndecan-4-deficient mice 
demonstrate reduced migration rate 
of fibroblasts and possibly impaired 
angiogenesis (Echtermeyer et al., 2001). 
RhoA and Rac1 are key proteins in cellular 
migration (Bar-Sagi and Hall, 2000) and 
were shown to be activated by syndecan-4 
( Saoncella et al., 1999; Bass et al., 2007). 
Because syndecan-1 is mostly 
epithelial, the question arose, whether 
there is a relationship between epithelial 
phenotype and syndecan-1 expression. 
As demonstrated by Kato et al. in 
1995, the loss of syndecan-1 causes 
epithelia to transform into anchorage-
independent mesenchyme-like cells. 
Mesenchymal cells have much higher 
migratory and invasive potential than 
epithelial cells. This prompted studies 
of syndecans in tumorigenesis, in which 
epithelial-mesenchymal transit ion 
occurs (Couchman, 2003). Indeed, there 
are several correlations between the 
loss of syndecan-1 and poor prognosis 
for patients with some head and neck 
carcinomas (Anttonen et al., 1999), as well 
as severity of the tumor grade in invasive 
cervical carcinoma (Rintala et al., 1999). 
Intriguingly, the loss of syndecan-1 is 
correlated with the loss of E-cadherin – 
a homophilic cell-cell adhesion receptor 
with certain tumor suppressor properties 
(Leppä et a., 1996). 
.
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Aims of the Study
2. AIMS OF THE STUDY
The aims of this study were to structurally and functionally characterize the known and 
novel GDNF receptors.
The speci? c aims were:
Structural characterization of the GDNF co-receptor GFR?1 and their complex??
Search for novel GDNF receptors??
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3. MATERIALS AND METHODS
The selected methods used in this study are presented in the table below:
Method Used in
Cell cultures and transfection
Primary neuronal cultures
Cell spreading assay
Neuronal migration assay
Neurite outgrowth assay
RNA isolation
Reverse transcription PCR
Molecular cloning
Site directed mutagenesis
Protein expression and puri? cation
Protein crystallization
X-ray diffraction 
Sequence alignment (ClustalW)
Protein tertiary structure modeling
Radiolabelled protein cell-based binding assay
Scintillation proximity assay
Surface plasmon resonance
Analytical heparin-sepharose chromatography
Protein phosphorylation assay
Protein iodination
Chemical protein cross-linking
Immunoprecipitation
I, II, III, IV
I
I
I
I, III
I
I
I, II, III, IV
II, IV
I, II, III, IV
II, IV
II, IV
IV, V
II, V
II, III, IV
I, II, III, IV
I, II
I, II
I, II, III, IV
I, II, III, IV
I, III, IV
I, II, III, IV
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heparin binding site usually consists of a 
stretch of basic amino acids (Lys, Arg or 
His). The canonical motifs were described 
by Cardin and Weintraub (1989) as B-B-
X-B-B or B-B-B-X-X-B-B, where B is 
a basic amino acid and X is any residue. 
However, there is a number of deviations 
from this motif. For instance, in collagen 
V the positively charged residues that 
constitute heparin-binding site are 
separated by two to five amino acids 
(K905R909R912R918R921R924) (Delacoux et al., 
1998).
Likewise, the GDNF’s secondary 
putative heparin-binding site consists 
of basic amino acids (R88K84K81) that 
are separated by 3 or 2 other residues. 
Nevertheless, this site can bind heparin 
because these residues are located on the 
same side of the ?-helix, with the side 
chains pointing to the same direction (Fig. 
7). It appears essential for heparin binding 
that the side chains of the basic residues 
are lined up. This is important because 
both heparin and HS are linear polymers 
with very limited winding capabilities. In 
addition, the spacing between lined basic 
residues de? nes the preferential binding 
of the protein to certain HS. The sulfation 
pattern of disaccharides constituting HS 
should comply with spatial arrangement 
of these basic amino acids for an effective 
interaction. This “lock-and-key” concept 
(Bourin and Lindahl, 1993; Kreuger et al., 
2006) could help to de? ne the structural 
determinants of protein-HS interaction.
By three independent methods – 
heparin-sepharose column chromatography, 
surface plasmon resonance (SPR) 
and scintillation proximity assay, we 
demonstrated that GDNF, NRTN and 
ARTN bind at high af? nity (10-50 nM) to 
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4. RESULTS AND DISCUSSION
4.1 HSPG syndecan-3 is a novel GFL 
receptor
GDNF was originally isolated using 
heparin-sepharose column chroma-
tography (Lin et al., 1993). Later, GDNF 
interaction with heparan sulfates (HS) was 
documented (Rickard et al., 2003). HS 
are also important for GFR?1-mediated 
RET signaling (Ai et al., 2007; Barnett 
et al., 2002; Tanaka et al., 2002). GFL 
interaction with HS was also shown 
to be important for biodistribution of 
exogenously administered proteins in the 
brain (Hamilton et al., 2001; Piltonen et 
al., 2009). The HSPG agrin may be one of 
the components of ECM interacting with 
GDNF (Iwase et al., 2005). However, for a 
long time the molecular identity of HSPG 
interacting with GDNF on the plasma 
membrane remained obscure. 
We demonstrated that neuronal 
transmembrane HSPG syndecan-3 directly 
binds GDNF, NRTN and ARTN, but not 
PSPN. Furthermore, syndecan-3 transmits 
the GFL-induced signal into the cell in 
the absence of the conventional GFL 
receptors. Alternatively, syndecan-3 serves 
as a co-receptor for the yet unidenti? ed 
GFLs receptor. 
GFLs may be considered the first 
growth factor signaling via HSPG. 
Another syndecan-3 ligand HB-GAM is 
an ECM molecule, not a growth factor. We 
also highlight two modes of GFLs action, 
as diffusible protein through GFR?1/RET 
signaling complex and as matrix-bound 
protein through syndecans (Fig. 8).
GDNF, NRTN and ARTN have a 
putative heparin-binding motif in their 
primary structure. GDNF’s primary 
heparin-binding site is in its unique 
N-terminal protrusion (I and Alfano et al., 
2007). PSPN lacks this motif. The putative 
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heparin, whereas PSPN binds with a three 
orders of magnitude lower af? nity. 
The presence of 2-O-sulfation was 
previously found crucial for the interaction 
between GDNF and heparin/HS (Rickard 
et al., 2003; Rider, 2003), with additional 
involvement of other sulfated groups. 
We confirmed this finding and further 
demonstrated that 6-O-sulfation and 
N-sulfation are also important structural 
determinants of GDNF interaction with 
HS (I).
In most tissues the HS molecules 
are less sulfated and more complex 
glycosaminoglycans than heparin. 
However, in the brain HS are highly 
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sulfated. To test whether the heparin-
binding GFLs bind to natural HSPGs, 
we assayed by SPR the direct interaction 
between immobilized GFLs and the ECD 
of syndecan-3 purified from rat brain 
and carrying natural HS side chains. 
The interaction occurs specifically via 
HS chains, because the heparinase III 
treatment strongly inhibited the interaction 
(data not shown). 
The dissociation constants derived for 
GDNF, NRTN and ARTN were in the 10-
50 nM range, demonstrating high af? nity 
for syndecan-3 and supporting the notion 
that these GFLs could also interact with 
other HSPGs, including those in the brain 
GDNF
NRTN ARTN
Heparin
Arg-88
Arg-125
Fig. 7. Putative heparin binding sites in GFLs. GDNF protomer contains two secondary putative 
heparin binding sites: in the ?-helix and in the ? nger 2. Basic amino acids constituting the sites 
are colored in light yellow. Manually docked heparin is surrounded by the surface of a calculated 
electrostatic potential. (transparent palettes were set as red and blue, corresponding to positive 
and negative charges). In NRTN and ARTN, basic residues constituting the putative heparin bind-
ing site are colored in light yellow and shown as ball-and-stick models.
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ECM (Iwase et al., 2005) and possibly in 
other tissues. PSPN binds syndecan-3 at 
much lower af? nity than the other GFLs. 
This also suggests that PSPN would lack 
af? nity to HSPGs in the ECM, thus raising 
an intriguing possibility that, unlike other 
GFLs, PSPN diffuses long distances in 
tissues ultimately reaching body fluids. 
Conceivably, it may act as hormone-type 
growth factor, which would explain the 
fact that PSPN and its speci? c co-receptor 
GFR?4 are expressed in different tissues 
(Lindahl et al., 2000; Lindahl et al., 2001; 
Lindfors et al., 2006).
GDNF interacts with syndecan-3 also 
on the cell surface as demonstrated by 
chemical crosslink of iodinated GDNF 
followed by immunoprecipitation with 
syndecan-3 antibodies. In addition, GDNF 
induces oligomerization of syndecan-3 in 
cells expressing CFP- and YFP-tagged 
receptors, as revealed by Förster resonance 
energy transfer (FRET) studies (I).
The development and maintenance 
of an organism is regulated by concerted 
action of ECM-immobilized (matrix-
bound) and diffusible (free) growth factors. 
To mimic the state in which matrix-bound 
proteins exist in vivo, we used surfaces 
coated with GFLs. When immobilized in 
this way, GDNF, NRTN and ARTN induce 
adhesion and spreading of cells in HSPG-
dependent manner. Previously, soluble 
GDNF was demonstrated to induce robust 
Src-kinase and PLC? activation in SHEP 
cells (Poteryaev et al., 1999). This cell line 
expresses GFR?1 and GFR?2 but lacks 
RET. Surprisingly, phosphatidylinositol-
specific phospholipase C (PI-PLC) 
treatment, which specifically cleaves 
GPI-anchor of the proteins, failed to 
decrease the spreading of SHEP cells 
on immobilized GFLs. In addition, 
preincubation of GDNF-coated surface 
with GDNF function-blocking antibodies 
(G90, Amgen Inc.) also did not inhibit 
spreading. These antibodies disrupt the 
GDNF interaction with GFR?1/RET 
by binding to the central part of GDNF 
(Xu et al., 1998), whereas the primary 
heparin-binding site is located on the 
unique N-terminal protrusion of GDNF 
(I and Alfano et al., 2007) and, therefore, 
remains uncovered by the antibodies.
Furthermore, the immobilized heparin-
binding-deficient mutant that lacks 38 
N-terminal amino acids (?N-GDNF) is 
unable to induce adherence of cells. This 
mutant fails to bind GFR?1 (Eketjäll et 
al., 1999) in the absence of RET but exerts 
full biological activity, promoting GFR?1-
mediated RET activation (I and  Eketjäll et 
al., 1999; Piltonen et a., 2009) in the same 
cells. Taken together, these facts support 
the hypothesis that matrix-bound GDNF, 
NRTN and ARTN can act directly through 
HSPG.
Immobilized GFLs are likely to 
induce the aforementioned effects by SFK 
activation. SFK activation in SHEP cells 
is also HS-dependent, since it is abolished 
by the heparinase III treatment and does 
not occur on immobilized ?N-GDNF. In 
addition, chemical SFK inhibitor (SU6656) 
(Paveliev et al., 2004) and an adenoviral 
Src dominant-negative construct inhibit 
GDNF-induced spreading but did not 
signi? cantly affect adhesion. 
Cell adhesion and spreading are 
important initial steps in many biological 
processes, such as cell migration and 
neurite outgrowth. Free GFLs are known 
to induce neurite outgrowth in many 
types of neurons (Airaksinen and Saarma, 
2002). Neurite outgrowth is important for 
long-term memory formation (Dityatev 
and Schachner, 2003), which is thought 
to occur in the hippocampus. Immobilized 
HB-GAM and GDNF both promote 
neurite outgrowth via syndecan-3 in 
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these neurons (Raulo et al., 1994 and I). 
Interestingly, syndecan-3 localizes in 
varicosities and growth cones as revealed 
by Raulo and colleagues (1994), and thus 
may participate in axon guidance.
Adult murine hippocampus expresses 
RET (www.brain-map.org) but embryonic 
hippocampal neurons express little or no 
RET (Trupp et al., 1997). Despite this 
fact, we observed that immobilized GDNF 
stimulates robust neurite outgrowth in rat 
E17 hippocampal neurons. Quantitative 
analysis demonstrated that the neurite 
outgrowth was neither affected by PI-
PLC treatment nor by NCAM function-
blocking antibodies, which suggests lack 
of involvement of conventional GDNF 
receptors. The number of neurites was 
significantly lower in cells treated with 
heparinase III, and neurons failed to 
form processes on the following non-
heparin-binding substrates, ?N-GDNF, 
PSPN, and BSA, con? rming role of HS 
chains in the interaction. Correspondingly 
cultures from syndecan-3-null mice had 
signi? cantly less neurons on immobilized 
GDNF. Likewise, the SFK inhibitor 
SU6656 prevented neurite outgrowth. It is 
important to note that, unlike Paratcha and 
co-authors (2003) who observed inhibition 
of GDNF-induced neurite outgrowth by 
NCAM function-blocking antibodies, we 
studied the initiation of neurite outgrowth 
(counting the number of neurites) and 
not their progression (i.e. neurite length). 
These are different processes governed by 
distinct mechanisms (da Silva and Dotti, 
2002). We conclude that the interaction 
between syndecan-3 and the immobilized, 
but not the free GDNF induces neurite 
formation in rat embryonic hippocampal 
neurons via SFK activation.
GFLs were shown to act  as 
chemotactic guidance molecules (Paratcha 
et al., 2006b). Soluble GDNF binding to 
GFR?1 and subsequent RET activation 
induce neurite outgrowth and neuronal 
migration. GDNF is well known to 
chemotactically promote migration (i.e. 
guide migration along concentration 
gradient) of enteric neuroblasts in the 
developing gastrointestinal tract (Moore 
et al., 1996; Pichel et al., 1996; Sánchez et 
al., 1996) and of olfactory bulb interneuron 
precursors (Paratcha et al., 2006b). 
ARTN-, GFR?3- and RET-de? cient mice 
have abnormalities in the migration and 
axonal projection pattern of the entire 
sympathetic nervous system. Indeed, 
soluble ARTN exerts its chemoattractive 
action by stimulating, through GFR?3/
RET, the migration of sympathetic 
neuroblasts (Nishino et al 1999; Honma 
et al., 2002). Our observation that the 
immobilized, but not the soluble GDNF 
induces hippocampal neurite outgrowth 
in a RET-independent manner suggests 
that GDNF also serves as a haptotactic 
(immobilized, short-range acting) ECM-
associated guidance molecule.
Notably, behavioral tests performed 
on the syndecan-3-deficient mice and 
GDNF heterozygous mice revealed 
impaired performance in tasks assessing 
hippocampal function (Gerlai et al., 2001; 
Kaksonen et al., 2002). 
Brain cortex development is a 
complex process that involves migration 
of neuronal precursors from subventricular 
zones along tangential migration route to 
the outer brain areas. Murine embryonic 
cortical neurons lack both RET and 
NCAM (Pozas and Ibáñez, 2005). In the 
cell migration assays, GDNF showed 
prominent induction of haptotactic 
migration in embryonic neural cells, 
suggesting that GDNF signals through 
a migration-associated receptor system 
(I). Binding of GDNF to this receptor is 
mediated by heparan sulfate chains, since 
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?N-GDNF did not induce migration in this 
assay. Strong evidence of GDNF binding 
to the syndecan-3 ectodomain led to the 
assumption that syndecan-3 would be the 
migration-inducing receptor for GDNF. 
We tested this hypothesis in syndecan-
3-de? cient embryonic cortical cells and 
observed reduced haptotactic migration 
in embryonic cortical neurons of the 
syndecan-3-knockout. The neurons from 
these animals and wild type neurons were 
equally well migrating when stimulated 
in this assay by laminin, suggesting that 
general migratory systems are intact 
in the knockout neurons (Hienola and 
Rauvala, unpublished). Interestingly, 
the highest concentration of GDNF 
could also stimulate migration of the 
knockout neurons, indicating the potential 
involvement of GFR?1 receptor (Pozas 
and Ibáñez, 2005). The finding that 
migration of cortical neurons depends on 
syndecan-3 further supports our view of 
syndecan-3 as a novel receptor for GDNF 
in neural cells. 
The migrat ion of  embryonic 
GABAergic cortical neurons in vivo
depends on GDNF and GFR?1. GDNF 
promotes the migration of GABAergic 
interneurons along the tangential migration 
route from medial ganglionic eminence 
(MGE) to developing cortex in mice (Pozas 
and Ibáñez, 2005). The question about the 
possible alternative GDNF receptor in the 
migrating interneurons remained open, as 
RET and NCAM receptors are missing in 
these cells.
We analyzed the density of GABA-
immunopositive cells in the cortex 
of syndecan-3-deficient mice. An 
approximately 30% decrease in the density 
of GABAergic neurons in the dorso-medial 
cortex (layers II-IV) was detected. This 
suggests a migration and/or differentiation 
defect of interneurons in syndecan-3 
knockout mice. The dorso-medial cortex 
(DMC) is the most distant part of the brain 
along the tangential migration route from 
neuron’s site of origin. Obviously, neurons 
have the longest way to travel to DMC. 
Therefore, mild migratory defects become 
a crucial obstacle for those neurons that 
depend on GDNF/syndecn-3 signaling 
pathway to migrate. Consistently, the 
cortical areas more proximal to the source 
of interneurons did not show such a clear 
difference. Although this analysis gives no 
conclusive evidence for syndecan-3 being 
the missing receptor for GDNF in the 
interneurons, it nevertheless is not against 
this hypothesis. 
In explants from wild-type MGE 
we observed the directed migration of 
GABAergic neurons towards GDNF-
soaked beads. Migration of the neurons 
obtained from the syndecan-3-deficient 
explants was signi? cantly compromised. 
However, neurons from this type of 
explants were capable of migrating 
towards BDNF, suggesting a GDNF-
speci? c effect of syndecan-3 ablation.
An intriguing possibility exists that, 
in addition to its possible signaling role, 
syndecan-3 acts as a co-receptor for 
GFR?1 in GDNF-induced migration of 
GABAergic neurons in embryonic cortex. 
In summary, this work highlights a 
new receptor for immobilized GDNF, 
NRTN and ARTN, which induces distinct 
biological effects and is fundamentally 
different from the Ret/GFR? or NCAM/
GFR? signaling systems utilized by free 
GFLs and (Fig. 8).  Our results clearly 
show that binding of immobilized GDNF 
to syndecan-3 alone triggers specific 
intracellular signaling leading to the 
activation of SFKs, cell spreading, neurite 
outgrowth and migration of embryonic 
cortical neurons. Thus GDNF, NRTN and 
ARTN are the ? rst growth factors to signal 
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via HSPGs. This ? nding is conceptually 
new because it implies distinct cellular 
responses to the protein in different 
physical state (free vs. immobilized).
 In addition, GFLs may be sequestered 
by HSPGs in the ECM and by syndecan-3 
on neuronal cell surfaces. Other syndecans 
may play a similar role in other tissues. For 
example, syndecan-1 is the likely GDNF 
binding receptor in developing kidney. 
This model also supports the idea that 
interaction of GFLs with HS concentrates 
GFLs in the vicinity of its conventional 
GFR?/RET receptors. Since syndecan-3 
has several HS side chains and each of 
them contains multiple GFL binding sites, 
we expect that a single syndecan-3 receptor 
can bind many GFL molecules. Therefore, 
compared to high-af? nity and low capacity 
GFR?/RET receptor complex, syndecan-3 
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Fig. 8. Hypothetical model of the syndecan-3 role in GFLs signaling. GDNF, ARTN and NRTN 
interacting with syndecan’s heparan-sulfates (HS) are sequestered  from GFR?/RET. A plausible 
heparanse-mediated cleavage of HS would release GDNF allowing it to interact with GFR?1/
RET as a free/diffusible protein. Syndecans may also serve as co-receptors for GFR?/RET by 
concentrating and presenting GFLs to the signaling complex. When immobilized in extracellular 
matrix (ECM) GDNF, NRTN and ARTN may induce signaling directly via syndecan-3 affecting 
actin dynamics.
36
Results and Discussion
is a low af? nity and high capacity GFLs 
receptor. Our model also predicts a 
new regulation step in GFL signaling - 
cleavage of HS or syndecan-3 ectodomain 
(Reizes et al., 2001) to regulate the release 
of soluble GFL that is required for GFR?/
RET receptor activation. However, the full 
extent of HSPG roles in GFL signaling 
remains to be elucidated.
4.2 The structure of GDNF-GFR?1
complex
The rat GFR?1 gene encodes for a cysteine-
rich protein with 468 amino acids including 
secretory and glycosylphosphatidylinositol 
(GPI)-anchoring signals. The conserved 
internally homologous cysteine pattern 
(e.g. 30 cysteines are conserved between 
GFR?1 and GFR?2) led to the proposal 
that GFR?1 contained three homologous 
cysteine-rich domains (Suvanto, 1997;
Airaksinen et al, 1999). In this model, 
the N-terminal domain 1 is linked by 
a hinge region to a core of domains 2 
(D2) and 3 (D3), which is followed by a 
C-terminal extension. 
As demonstrated by Scott and Ibáñez 
(2001), GDNF binds to the central domain 
of the GFR?1, which corresponds to joint 
D2 and D3 in Suvanto’s model (Suvanto,
1997). Specifically, hydrophobic site 
(213MLF) and arginine triplet (224RRR) 
were shown to be crucial for GDNF 
binding to GFR?1. Interestingly, these 
GFR?1 mutants were fully active in 
mediating RET activation by GDNF. 
This ? nding, together with previous work 
from the Ibáñez laboratory (Eketjäll et al., 
1999), argues in favor for the existence 
of a substantial fraction of preformed 
GFR?1/RET complex on the cell surface. 
This complex may provide additional 
binding sites for GDNF either by rendering 
conformational change to GFR?1, 
revealing cryptic binding sites, or by direct 
GDNF-RET interaction. Our mutagenesis 
data (IV) also support this hypothesis. 
GDNF binding to GFR?1 variants - 
Phe213Ala, Arg224Ala, Arg225Ala – is 
signi? cantly impaired or undetectable, but 
all three proteins mediate RET activation 
(IV).
Furthermore, we observed a substantial 
increase in the binding of radiolabelled 
GFR?1 (in the absence of GDNF) to the 
surface of the MDCK cells expressing 
RET (Popsueva et al., 2003) compared to 
cells lacking RET (unpublished data). This 
? nding also supports the direct interaction 
between GFR?1 and RET in the absence 
of GDNF.
The question whether GFR?1/RET 
complex is pre-formed has a therapeutic 
significance. Small molecule XIB4035 
can bind to GFR?1 and activate RET 
(Tokugawa et al., 2003). This molecule is 
a quinoline that has earlier been used to 
treat Protozoan infections. As XIB4035 
weighs less than 500 Da, it is unlikely 
that it activates GFR?1/RET in the same 
manner as GDNF, which “crosslinks” 
two GFR?1 molecules. We, therefore, 
suggested that the mechanism of XIB4035 
action is by binding to a “hot-spot” on 
the preformed GFR?1/RET complex 
triggering a conformational change (V). 
As RET in the crystal adopts an 
“active” conformation regardless of its 
phosphorylation status (Knowles et al., 
2006), the signaling may be initiated by 
trans-phosphorylation of the residues that 
are distant from the catalytic site (e.g. 
Y1062, Y1096). This is in accordance 
with the classic model of RTK signaling 
(Schlessinger, 2000). It is conceivable 
that XIB4035 binding to a “hot-spot” 
in GFR?1/RET complex would change 
its conformation and align the apposing 
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kinase domains into positions suitable for 
trans-phosphorylation of distal tyrosine 
residues.
Expression and crystallization of the 
full-length GFR?1 poses a significant 
challenge. Therefore, we expressed and 
tested for binding ability a number of 
protein variants (12 constructs). Initially, 
only the third domain produced well-
diffracting crystals. Crystal structure 
at 1.8Å resolution was reported (IV), 
revealing a new protein fold. It is a ? ve-
helix bundle with ? ve disul? de bridges. 
The helix ?1 is connected at 80º to 
?2, followed by the loop 1. Helix ?3 is 
hydrophobic and antiparallel to ?2, packing 
against it.  The fourth helix is connected 
to ?3 by the long loop (loop 2) that could 
only be partially visualized in the initial 
structure. This region contains many 
hydrophobic amino acids and, together 
with ?3, was later demonstrated to be an 
interface for D2, assuming antiparallel 
?-strands structure (II). The helix ?4 is at 
70 º to both ?2 and ?3. The helix ?5 is an 
extension of ?4, which stabilizes positions 
of ?2 and ?3.
 This helical arrangement resembles a 
triangular spiral, with 5 disul? de bridges 
locking the “corners” of the triangle. 
The network of disulfide bridges and 
the hydrophobic residues buried inside 
the helical bundle, suggest that D3 folds 
independently from other domains.
The structural data on D3 allowed 
us to model the homologues D2. Earlier 
analysis (Eketjäll et al., 1999; Scott and 
Ibáñez, 2001) and our crystallographic 
and mutagenesis data lead us to construct 
the first structural model for GDNF-
GFR?1 interaction. This model suggested 
that GDNF binds at the interface between 
the second and third GFR?1 domains. 
The mutagenesis appeared to confirm 
this model as Arg224, Arg225 and Ile229 
were thought to mediate GDNF-GFR?1
interaction and their substitution resulted 
in impaired GDNF binding. However, 
as we learned, this model of interaction 
turned out to be wrong. 
Our later study (II) and the structure 
of GFR?3-ARTN (Wang et al., 2006) 
revealed symmetrical (GDNF)2(GFR?1)2
complex (Fig. 9) with GDNF and ARTN 
binding to a center of the D2 “triangular 
helix spiral”. We showed that at the center 
of the interface an ion triplet is formed: 
Arg171GFR?1 –Glu61GDNF-Arg224GFR?1,
which is critical for the interaction. This 
triplet is conserved among GFLs and 
GFR?s, allowing all four ligands to 
signal via GFR?1/RET receptor complex 
(Sidorova et al., unpublished). Another 
critical residue is Ile175, which is present 
in GFR?1 and GFR?2. In GFRa3 Ile175 is 
substituted with glycine, which precludes 
GDNF-GFR?3 interaction when RET is 
absent.
The structure of D2 is similar to D3. 
The length and the relative positions of 
the ? rst three helices are almost identical. 
Instead of beta-strands in loop 2, a short 
helix ?4 is present in D2. Helices ?5 and 
?6 are analogous to ?4 and ?5 in D3. 
The angle of these helices relative to ?2
and ?3 is smaller in D2 and, as its ?6 is 
rudimentary, the whole domain is more 
compact than D3. 
Residues of helix ?5 interact 
simultaneously with GDNF and with 
loop 2 of D3. Helices ?3, ?4 and ?6 also 
contribute to the interface with D3. 
The sucrose octosulfate (SOS), a 
disaccharide heparin mimetic, binds to 
GFR?1/GDNF and co-purifies with the 
complex. In the crystal structure SOS can 
be clearly seen in the highly positively 
charged region on GFR?1 surface between 
the second and third domains, suggesting 
a role of HS in GDNF signaling. 
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SOS binds a stretch of positive 
amino acids in ?3 of D2 (R189-K202) 
and R257/R259 in ?2 of D3. The side-
directed mutagenesis of GFR?1 (R190A/
R197A) reduced GDNF-induced RET 
phosphorylation by 3 folds. This suggests 
that either heparin-binding is critically 
important for GDNF-signaling or/and 
that these GFR?1 residues participate in 
interaction with RET.
The exact role of HS in GFR?1/
RET activation by GDNF is debated. 
Barnett at al. (2002) demonstrated that 
HS on the cellular surface are essential 
for GDNF-signaling and biological 
effects. As exogenous heparin inhibited 
RET phosphorylation, they concluded 
that the role of HS is to concentrate 
GDNF in GFR?1/RET vicinity. The free 
heparin competed with HS on the plasma 
membrane. Two other studies reported 
neurite inhibition by exogenous heparin 
(Ai et al., 2007; Alfano et al., 2007). 
Our structural data suggest an 
alternative mechanism of GDNF signaling 
inhibition by the free heparin. It may 
compete with RET for the same binding 
site on GFR?1 (II).
However, Tanaka et al. (2002) and 
our recent cellular data indicate that HS 
may stimulate GDNF signaling in vitro
(Piltonen et al., 2009). 
These contradictory facts need to 
be critically examined. For example, 
neurite outgrowth inhibition by the free 
heparin (Ai et al., 2007; Alfano et al., 
2007) might have been a manifestation 
of heparin (or heparin preparation 
impurities) toxicity. The researches used 
heparin of different molecular weights, 
which further complicates the analysis of 
the results. On the other hand, Piltonen 
et al. (2009) have demonstrated that ?N-
GDNF, which interacts with GFR?1 much 
weaker than wild type GDNF (Eketjäll 
et al., 1999), signals more ef? ciently at 
Fig. 9. GDNF complex with GFR?1. GDNF interacts with the central part of GFR?1 domain 
two. The critical interaction is formed by an ion triplet GFRa1Arg-171(R171)-GDNFGlu-61(E61)-
GFRa1Arg-224(R224). Helices of domain 2 of GFR?1 are designated ?1-?6. The heparin mimetic 
sucrose octosulfate (SOS), represented as sticks, binds to the interface of domains two and three, 
and this area is suggested to interact with RET. 
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is likely to be more ? exible than ARTN 
(Parkash and Goldman, 2009). 
The structural differences between 
GDNF and ARTN lead to quantitative 
differences in their signaling. GDNF 
activates MAPK signaling more rapidly 
and robustly than ARTN (II). The levels 
of RET phosphorylation induced by 
GDNF and ARTN are comparable but 
minor differences in dynamics of RET 
phosphorylation were observed (Coulpier 
et al., 2002). The downstream ampli? cation 
of the signal leads to quantitative 
differences in gene expression.
4.3. The putative structure of GDNF-
GFR?1-RET complex 
Although the molecular architecture of 
GFL-GFR? complexes became apparent, 
the structure of the whole GFL-GFR?-
RET receptor complex remains to 
be elucidated. Our biochemical data 
suggested that the interface between 
RET and GFR?1 is located close to the 
SOS binding site. The positively charged 
Arg190, Lys194, Arg197, Lys202, Arg257 
and Arg259 (Fig. 9) may interact with 
the cysteine-rich domain (CRD) of RET, 
which is negatively charged. 
Using chemical  cross-l inking 
followed by MALDI mass spectrometry 
(MS), Amoresano and colleagues (2005) 
demonstrated that the C-terminal fragment 
of GDNF interacts with the 191RCHKALR
fragment of GFR?1. They also suggested 
the interaction between GDNF N-terminal 
protrusion and the N-terminal domain of 
GFR?1. However, the suggested high 
? exibility of N-terminal region of GDNF 
(Eigenbrot and Gerber, 1997) might 
result in unspeci? c association between 
these regions. The detected interaction 
between the ? rst domain of GFR?1 and 
RET-CRD may also be attributed to the 
sub-optimal concentrations than wild 
type GDNF. In addition, the effect of 
HS on GDNF-signaling may depend on 
the source of GDNF. We have observed 
signi? cantly lower signaling enhancement 
by HS when we used glycosylated GDNF 
produced in insect cells compared to E. 
coli-produced protein (Sidorova et al., 
unpublished). These two facts suggest 
an unspeci? c interaction between GDNF 
and HSPG on the cell surface (or binding 
to plastic of the labware), resulting in 
sequestering of GDNF from the solution, 
thus decreasing its effective concentration. 
Co-administration of heparin and GDNF 
results in shielding GDNF’s excessive 
positive charge by negative heparin 
molecules, preventing GDNF from 
unspeci? c interactions. 
Another interesting crystallographic 
observation was that three N-terminal 
residues of GDNF from one GDNF-
GFR?1 heterodimer interact with SOS 
bound to another heterodimer. GFR?1 is 
a ligand-induced cell adhesion molecule 
(LICAM) (Ledda et al., 2007), which 
plays a role in synapse formation. The 
crystallographic interaction between two 
GDNF/GFR?1 heterodimers (II) suggests 
that on the plasma membrane GDNF/
GFR?1 oligomerization is mediated 
by HS. As HS are long molecules, the 
intercellular cross-linking of heterodimers 
into larger aggregates is feasible.
The comparative structural analysis 
of GDNF and ARTN and their complexes 
with corresponding GFR?s suggests 
distinct bend angle between the “heel” 
and the “fingers”. (Eigenbrot and 
Gerber, 1997; Silvian et al., 2006). The 
larger angle in GDNF results in shorter 
distance between two GFR?1 (Wang et 
al., 2006 and II).  GDNF can adopt several 
conformations in the crystal and, thus, 
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high mobility of domain 1, as GFR?1
domain 1 is separated from the second 
domain by a long and likely disordered 
linker.
The homology between domains 1, 2 
and 3 allows the construction of the model 
for the domain 1 (D1). The resulting model 
B
Membrane TM TM
Membrane TM TM
90º
Fig. 10. The model of the GFR?1/RET signaling complex. 
A. RET ectodomains (shown in tinges of violet) interact homotypically as well as with the cen-
tral part of GDNF/GFR?1 complex, assuming “saddled” position (McDonald, 2008, Conference 
presentation). GDNF in complex with GFR?1, represented by domains 2 and 3, is shown as 
electrostatic potential surfaces (blue – positive and red – negative charge).  TM – transmembrane 
domain.
B. As in Fig. 10, rotated 90º
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has a similar to D2 fold, and it is an all-?
four-helix bundle with 3 cystines (Fig. 2). 
The ? st domain of GFR?1 is important 
for GDNF binding (III). GFR?1 lacking 
first domain binds GDNF two times 
less tightly than the full-length protein. 
An impaired binding has biological 
consequences - GDNF-stimulated PC6 
cells produce significantly less neurites 
when transfected with truncated GFR?1. 
D1 may interact with GDNF directly 
(Amoresano et al., 2005). 
An alternative role that D1 may play 
is in protein sorting (Scott and Ibáñez, 
2001). It was suggested that N-glycans 
participate in apical sorting of GPI-
anchored proteins (Benting et al., 1999).
Jing et al. (1996) predicted that GFR?1
contains three N-glycosylation sites, 
including one at N-terminus. MALDI-TOF 
mass spectrometry (MS) of the full-length 
and of the truncated receptor showed that 
both variants weigh more than predicted. 
The modi? cation of the full-length GFR?1
is larger, suggesting that D1 is also post-
translationally modi? ed. In electro-spray 
MS the truncated receptor was ionized and 
a set of masses around 37 kD was detected. 
The mass heterogeneity corresponds 
to masses of N-acetylglucosamine and 
hexose (III).
Another possible role of D1 is an 
interaction with HS. D1 is positively 
charged – its calculated isoelectric point 
is 9.21 and it may interact with HSPG 
on the plasma membrane. Full-length 
GFR?1 elutes from a heparin column at 
higher ionic strength than N-terminally 
truncated receptor (II). The physiological 
relevance of this interaction remains to be 
established.
R E T c a d h e r i n - l i k e  d o m a i n s 
(CLDs) were modeled by homology 
with N-cadherin (Anders et al., 2001). 
However, modeling of the cysteine-rich 
domain of RET poses a problem because 
it lacks profound secondary structural 
features and the pattern of cysteines is 
not conserved. Nevertheless, the RET-
CRD shares 18% identity with laminin 
gamma 1 chain. An alignment of cysteines 
allows the generation of the gross 
model of RET-CRD (Fig. 2). The model 
reveals two loops protruding in the same 
direction. Earlier, a similar type of loops 
in CRD domain 2 and 4 of EGFR were 
shown to be important in autoinhibition 
and dimerization. However, in the fully 
assembled RET signaling complex these 
loops would rather interact with GFR?1/
RET than homotypically. The possibility 
exists that these loops can still promote 
RET dimerization when dissociated from 
GFR?1. Indeed, as demonstrated by Trupp 
et al. (1997) overexpressed RET has a high 
propensity for activation in the absence of 
GFR?1. Transmembrane domains of RET 
may also contribute to self-association 
(Kjær et al., 2006)
Our current structural understanding 
of the extracellular part of the RET 
signaling complex is summarized in the 
Fig. 10. The model represents a complex 
with a (GDNF)2:(GFR?1)2:(RET)2
stoichiometry  (domain 1 of GFR?1 is 
omitted). According to the model, RET is 
bent towards GDNF/RET and to plasma 
membrane. The RET-CLDs are suggested 
to participate in homophilic interaction 
and to engage in direct interaction with 
GFR?1 and/or GDNF. This model is 
compatible with the pre-formed GFR?/
RET complex hypothesis (V) and may be 
helpful in the development of clinically 
useful GFL-mimetics.
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1. We identi? ed neuronal heparan sulfate proteoglycan syndecan-3 as a novel receptor 
for GDNF, NRTN and ARTN. Syndecan-3 may transduce the GFL signal directly 
into the cells or serve as a co-receptor for either GFR?/RET or GFR?/NCAM or 
for an as yet unidenti? ed receptor. The physiological relevance of this signaling 
is to promote the  migration of GABAergic interneuron precursors towards the 
developing cortical layers.
2. We characterized GDNF interaction with its co-receptor GFR?1 using biochemical 
and cell biological methods and solved the crystal structure of their complex.
3. We proposed a model for the fully assembled GDNF signaling complex and 
hypothesized on how small molecules mimicking GDNF can activate the receptor.
5. SUMMARY AND CONCLUSIONS
Summary and Conclusions
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